BENCHMARKING AND ENHANCING LARGE LAN GUAGE MODELS FOR BIOLOGICAL PATHWAY REA SONING

Anonymous authors

Paper under double-blind review

ABSTRACT

Large language models (LLMs) have demonstrated remarkable performance across various domains of biology, but their ability to reason about biological pathways remains underexplored. This includes reasoning about how perturbations in biological systems lead to various downstream effects through complex intermediate processes. Such reasoning is crucial for explaining and predicting biological phenomena, as well as for formulating hypotheses and designing experiments.

In this study, we investigate whether LLMs can effectively understand and reason about biological pathways by introducing BioMaze, a comprehensive benchmark focusing on reasoning about the effects and mechanisms of natural and synthetic interventions—such as mutations, infections, or treatments—on various downstream targets under different conditions through complex intermediate pathway processes. BioMaze spans multiple biological domains and is categorized along three reasoning dimensions, capturing various aspects of pathway reasoning.

We evaluate LLMs using the BioMaze benchmark with reasoning methods like Chain-of-Thought (CoT) and pathway graph-augmented approaches. Results show that while LLMs can understand mechanisms in natural organisms, they struggle with predicting phenomena after perturbations, highlighting their limitations in reasoning about biological pathways. To address these challenges, we propose PATHSEEKER, a novel LLM agent that interactively reasons through subgraph-based navigation within pathway graph. This approach enhances LLMs' reasoning in biological pathways by leveraging pathway graph augmentation, particularly in cases involving perturbations, potentially bridging the gap between LLMs' current capabilities and the complexities of biological systems.

034 035

037

006

007

008 009 010

011

013

014

015

016

017

018

019

021

023

025

026

027

028

029

031

032

033

1 INTRODUCTION

Large Language Models (LLMs) have recently shown impressive performance in science across various domains, including mathematics (Yu et al., 2023), chemistry (Liu et al., 2023b), biology (Hayes 040 et al., 2024; Madani et al., 2020), and materials science (Zheng et al., 2023; Park et al., 2024). In the 041 biological domain specifically, recent studies have demonstrated the potential of LLMs in tackling 042 challenging tasks such as protein design (Valentini et al., 2023; Hosseini et al., 2024), drug discovery 043 (M. Bran et al., 2024; Liu et al., 2023c), clinical trial analysis (Singhal et al., 2023; Jin et al., 2023), 044 and experiment design (AI4Science & Quantum, 2023). Although LLMs are increasingly capable of addressing more complex, real-world problems within the biological sciences, their fundamental understanding, reasoning, and metacognitive abilities (Wei et al., 2022; Wang et al., 2022; Kojima 046 et al., 2022) toward these scenarios-specifically in comprehending and reasoning through the in-047 tricate, multi-step processes involved in biological systems—have yet to be thoroughly explored. 048

Biological systems are composed of complex networks called pathways, which function as intercon nected units involving various components, such as enzymes, substrates, and signaling molecules.
 These components interact in a highly coordinated manner, enabling the integration of multiple signals and precise regulation of system responses. As a result, intervention in a single component of a
 pathway—such as mutations, inhibitions, or pathogen infections—can influence other components within the organism via intricate, multi-step intermediate processes.




Figure 1: Illustration of BioMaze task and reasoning method with or without additional biological pathway graph data guidance. The task of BioMaze focuses on reasoning about the effects and mechanisms of natural components or synthetic interventions on various downstream targets under different conditions through complex intermediate pathway processes.

A wide range of biological phenomena can be explained and predicted by understanding and reasoning about biological pathways. In biological research, this understanding is essential for formulating hypotheses, designing experiments, and predicting and interpreting results. For example, blocking muscarinic M3 receptors in taste cells triggers a sequence of events, including reduced calcium mobilization in Type II taste cells, a weakened role of CALMH1 in ATP release, and diminished taste-evoked responses in taste sensory fibers, as shown in Figure 1. These insights can be useful for toxicity analysis, designing experiment groups with induced taste suppression, and developing treatments for decreased sense of taste.

076 Given the complexity of biological systems and the importance of understanding pathway interac-077 tions, the application of LLMs to analyze and predict their behavior presents both opportunities and 078 challenges. In this paper, we first introduce BioMaze, a benchmark that serves as a crucial start-079 ing point for assessing LLMs' ability to comprehend and reason about realistic biological pathway phenomena. BioMaze compiles biological pathway phenomena from literature and generating cor-081 responding questions and answers. These questions span multiple biological domains, focusing on 082 predicting the effects and mechanisms of natural and synthetic interventions on various targets un-083 der different conditions through complex intermediate processes. Targets may include individual 084 components, component interactions, their roles in biological processes, or larger-scale functions.

085 We conducted extensive evaluations of LLMs using the BioMaze benchmark, incorporating reasoning methods such as Chain-of-Thought (CoT) and pathway graph-augmented approaches (Li et al., 087 2023a; Sun et al., 2023; He et al., 2024). The results show that while LLMs demonstrate an understanding of mechanisms within natural organisms, they struggle to predict phenomena and grasp mechanisms when perturbations are introduced into the system—such as during interventions or 090 when organisms are in altered conditions. This reveals that LLMs' causal reasoning abilities for biological pathways are limited. To address these challenges, we then propose a novel approach, 091 PATHSEEKER, an LLM agent that interactively reasons through subgraph-based navigation while 092 exploring the pathway graph. This method enhances LLMs' performance in complex biological reasoning tasks by effectively leveraging pathway graph information as blueprints in reasoning, es-094 pecially in the case of interventions. In summary, our contributions are as follows: 095

096

098

099

102

065

066

067

- We introduce BioMaze, a comprehensive benchmark designed to assess LLMs' ability to understand and reason about biological pathways. BioMaze focuses on evaluating the models' capacity to predict the effects and elucidate the mechanisms of both natural and synthetic interventions—such as mutations and infections—on various downstream targets under diverse conditions through complex intermediate pathway processes. The benchmark spans multiple biological domains and is structured along three dimensions: interventions, conditions, and target types.
- We conduct extensive evaluations of LLMs using BioMaze, incorporating advanced reasoning methods such as CoT and pathway graph-augmented approaches. Our results reveal that while LLMs demonstrate proficiency in understanding mechanisms within natural organisms, they encounter significant challenges when predicting phenomena and comprehending mechanisms in perturbed systems. These findings highlight critical limitations in LLMs' reasoning capabilities within the domain of biological pathways.

• We propose PATHSEEKER, a novel LLM agent approach that employs interactive, subgraph-based exploration to navigate pathway databases during reasoning. This method enhances LLMs' reasoning in biological pathways by leveraging pathway graphs as structured blueprints, especially for the case with interventions, potentially bridging the gap between LLMs' current capabilities and the complexities of biological systems.

2 RELATED WORK

Biological Scientific Question Answering Previous studies have explored the potential of language 117 models in the biological scientific domain (Lu et al., 2022; Vilares & Gómez-Rodríguez, 2019; Jin 118 et al., 2021; Pal et al., 2022). MEDHOP (Welbl et al., 2018) and PubMedQA (Jin et al., 2019) inves-119 tigated biological scientific QA in the form of reading comprehension. BioASQ-QA (Krithara et al., 120 2023) proposed a realistic question-answering benchmark for the information needs of biomedical 121 experts. A few studies have examined language models' ability to understand biological pathways. 122 Chatpathway (Li et al., 2023b), Park et al. (2023), and Azam et al. (2024) specifically investigated 123 language models' capacity for completing biological pathways. Different from previous tasks, this 124 work introduces a novel task for practical biological pathway phenomenon reasoning, addressing 125 the reasoning capacity of LLMs. See Appendix A.13 for a more detailed comparison.

126 Graph-augmented Language Model Several studies have explored augmenting LLMs with graph 127 data. In particular, some works enhance LLMs by encoding graph data as text (Ye et al., 2023; 128 Wang et al., 2024; Fatemi et al., 2023), or tuning LLMs specifically for graph-based tasks (Liu et al., 129 2023a; Tang et al., 2024; He et al., 2024; Zhao et al., 2023; He & Hooi, 2024). Augmented LLMs 130 have been applied to knowledge-based QA (Sun et al., 2023; He et al., 2024; Li et al., 2023a; Jin 131 et al., 2024; Cheng et al., 2024; Edge et al., 2024) and graph tasks like property prediction (Wang 132 et al., 2024; He et al., 2023). Some studies leverage graph structures for complex reasoning tasks (Jiang et al., 2023; Besta et al., 2024). Most large graph databases use retrieval mechanisms (He 133 et al., 2024; Li et al., 2023a), while others employ LLMs as interactive agents for navigation (Sun 134 et al., 2023; Jin et al., 2024; Li et al., 2024). This work introduces a more efficient agent-based 135 approach using subgraph navigation and reasoning to improve pathway database exploration. 136

137 138

108

110

111

112

113 114

115 116

3 BENCHMARK: BIOMAZE

139 140 141

3.1 DATASET CREATION

142 To gather realistic biological pathway phenomena, particularly those involving interventions, as il-143 lustrated in Figure 1, the data for BioMaze is sourced from over 6,000 biological pathway research 144 papers. These studies involve carefully designed intervention experiments supported by pathway 145 mechanisms to observe how biological systems respond. We extract detailed experimental observa-146 tions and their contexts directly from the abstracts. Importantly, our focus is on the specific experi-147 mental phenomena observed and reported, rather than the final conclusions drawn by the researchers. This is essential for our goal of predicting detailed events in the benchmark. The dataset creation 148 involves prompting the large language model, and in this study, we choose LLaMA3.1-405B (Dubey 149 et al., 2024) and GPT-4 as the models for data creation. 150

151 After extracting the phenomena, we convert each one into either a True/False or open-ended ques-152 tion, depending on its content. Each question is paired with corresponding labeled answers. We then 153 apply multiple data filters and human validation steps to ensure the correctness, quality, and relevance to biological pathways. The correctness of each question is validated by checking whether 154 LLMs can answer it accurately using the original paper content. Question quality is ensured through 155 several filters, removing questions that are poorly defined, unpredictable (e.g., asking for specific 156 measurement values), query more than one fact, are trivial with answers revealed in the question's 157 context, or are unrelated to biological pathways. After all the filters, BioMaze contains 1.3k high-158 quality questions for biological pathways reasoning. 159

The questions of BioMaze cover a wide range of biological domains, including metabolism, genetic information processing, environmental information processing, cellular processes, organismal systems, and human diseases. The biological domain distribution is illustrated in Figure 2 (left).

195

Dimension	Category	Example (abbreviated)	Illustra	tion
	Normal	What is the effect of AMPK activation on SIRT1 activity in mouse skeletal muscle?		C
Inquiry Type	Perturbed	What is the effect of GogB-deficient Salmonella on NFkappaB activation and proinflammatory re- sponses in infected mice?		(
	Natural	How does apelin affect TNFalpha inhibition on brown adipogenesis?		C
Extra Condition	Intervened	What is the role of BID in BAX activation in AIF- mediated necroptosis after MNNG treatment?		(
	Single	What happens to AQP2 upon ADH stimulation?		(
Investigation Target	Interaction	How does the influenza protein NS1 affect the ac- tivation of RIG-I by viral ssRNA?		(
	Function	What is the effect of losing 11beta-HSD2 from the fetus and fetally derived tissues on cerebellum development?		(
	0	Metao.		
	arcet ove	This disease: bacteriar		
	Add a state			
	Cancer: specific Vices Cardovescular disease Human	Diseases	and the second distances	
	Endocrine system	Concern Press Person Pe	ervened Single	
	amune system	and the second s	Nea Function	
	and and and a second se	the second		
	*****	Partie		

Table 1: Task example for each category.

189 Figure 2: Dataset biological domain and reasoning type distribution. Left: BioMaze covers six 190 main domains: metabolism, genetic information processing, environmental information processing, 191 cellular processes, organismal systems, and human diseases. Right: BioMaze is categorized along 192 three dimensions of reasoning types: inquiry type, extra condition, and investigation target. 193

194 3.2 REASONING TYPE CATEGORIES

The questions in BioMaze are categorized across three dimensions: inquiry type, extra condition, 196 and investigation target, leading to varying types and difficulties of reasoning, as shown in Table 1. 197 More full question cases are in Appendix A.1. The distribution of the three dimensions' questions 198 is shown in Figure 2 (right). We introduce each category of the dimensions below: 199

Dimension 1: Inquiry Type 200

201 Category 1: Normal Source This category involves predicting the effects of natural components 202 in their normal state within a biological pathway. Tasks here focus on understanding the funda-203 mental mechanisms of pathways in biological systems. The goal is to evaluate how well LLMs can 204 comprehend and explain typical biological pathway functions.

205 Category 2: Perturbed Source This category deals with predicting the effects of external inter-206 ventions or treatments, such as mutations, infections, or experimentally introduced elements, on 207 downstream targets within pathways. Tasks emphasize reasoning about how these interventions 208 alter pathway functions. This mirrors real-world biological research, where the focus is often on 209 understanding how such interventions influence biological systems and their downstream targets.

210 **Dimension 2: Extra Condition** 211

212 **Category 1: Natural Condition** In this category, the task predicts the impact of the inquiry source under an organism's natural conditions, meaning no additional treatments are applied to the biolog-213 ical system beyond the inquiry source. For example, in Table 1, the natural condition question asks 214 about the mechanism through which apelin affects TNF-alpha inhibition in brown adipogenesis, 215 with no extra interventions present in the pathway.

Category 2: Intervened Condition This category assesses the inquiry source's impact when com bined with other factors like mutations, infections, or interventions, focusing on how these conditions alter the pathway. For example, the question in Table 1 examines BID's role after MNNG
 treatment, where the pathway differs from its natural state. Enhancing performance here is crucial for modeling complex biological scenarios, such as predicting treatment outcomes and drug
 interactions, as it shows how multiple factors interact within a system.

222 Dimension 3: Investigation Target

Category 1: Single Component as Target This category focuses on investigating the effect of the source on a specific component within the pathway, such as its expression, activation, or inhibition.

Category 2: Components Interaction as Target This category examines the effect of the source
 on interactions between components within the pathway. It may involve understanding how down stream components interact with each other or their roles in regulating pathway processes. For
 example, the question of this category in Table 1 queries influenza protein NS1's effect on the
 downstream process that viral ssRNA activates RIG-I.

Category 3: Function as Target This category evaluates the effect of the source on broader biological functions or macro-level phenomena within the organism. It addresses more comprehensive system behaviors, helping to link pathway-level changes with organism-wide outcomes, which are crucial for scenarios like understanding health and disease processes.

235 236

267 268

3.3 PATHWAY GRAPH AUGMENTATION

Text-only reasoning methods like CoT generate reasoning steps directly from LLMs based on a given question. However, reasoning about biological pathways poses challenges due to their graph-based nature, requiring LLMs to not only have an implicit understanding of these pathways but also effectively plan and execute complex reasoning steps.

This work addresses the question: Do large language models require pathway graph data augmentation to reason effectively about biological systems? Providing explicit pathway graphs could serve as structural blueprints, enhancing reasoning from both knowledge and logic perspectives. We formalize this problem as:

$$a = G(\mathcal{E}, o),\tag{1}$$

where G represents the language model, \mathcal{E} denotes the task instruction (including the question), o refers to the observation from the augment pathway graph database, and a signifies the model output which could be the answer as well as the reasoning process.

Pathway Graph Database To augment LLMs with reasoning in biological pathways, we created a pathway graph database based on KEGG (Kanehisa & Goto, 2000), a collection of pathway maps on metabolism and various cellular and organismal functions widely-used resource among biologists. We compiled all available pathway networks and maps from KEGG and integrated all of them into a single pathway graph database. The statistics for the pathways are in Appendix A.5. Each entry in the dataset is provided with a detailed description and function corpus. The graph is structured in triples as [Head IDs, Tail IDs, (Relation Type, Biological Process IDs)].

Pathway Graph Database API When the language model accesses the pathway database, it may need to retrieve relevant triples from the pathway graph using APIs like Search_Node, Search_Edge, and Search_Triple (Sun et al., 2023; Li et al., 2023a). Our pathway database supports these core retrieval APIs based on detailed descriptions and functional corpora. These APIs are essential for enabling various graph-augmented reasoning methods in LLMs.

Since the connectivity of the pathway graph is crucial for enhancing reasoning in biological systems, we also developed the retrieval API designed to find the optimal connected subgraph $S^* = \text{Search}_{\text{Subgraph}}(query, N)$, where S^* is the retrieved subgraph, query represents the query content, such as keywords, and N is the target size. The goal is to match a given target size as closely as possible while maximizing the matching score. This is formulated as a optimization problem:

$$S^* = \text{Search}_{\text{Subgraph}}(query, N) = \underset{S \subseteq P, S \text{ is connected}, |S|=N}{\operatorname{argmax}} \sum_{i \in V_S \cup E_S} \operatorname{score}(i, query)$$
(2)

Here, the overall pathway network is denoted by P, with V_S and E_S representing the node and edge sets of subgraph S. The details of the implementation are described in Appendix A.6.




Figure 3: PATHSEEKER allows interactive browsing of the pathway graph database by navigating through subgraphs. At each step, PATHSEEKER can perform either a global subgraph search or a local search around a previously explored pathway step. This functionality enables PATHSEEKER to fully leverage the augmented pathway graph database during biological pathway reasoning.

Graph-to-Text Encoder For retrieved results which is a list of triples (e.g., the output of Search_Triple or Search_Subgraph), the result S is encoded into text o using the following process:

$$p = \text{TripleToText}(\text{DFSOrder}(S)) \tag{3}$$

Function DFSOrder arranges the triples in depth-first search (DFS) order. Unlike other methods, such as relevance scoring, DFS order more closely aligns with the reasoning process through the subgraph, reflecting the natural progression of biological functions. The ordered subgraph \hat{S} is converted into text format for the LLM by encoding each triple as a string in the following format: Head | Tail | Relation and Biological Process.

4 METHOD: PATHWAY REASONING AGENT PATHSEEKER

As we evaluated several graph-augmented reasoning methods, we found that current graphaugmentation methods' performance is limited by their ineffective utilization of the pathway graph database for reasoning. In this work, we propose a general solution for biological pathway reasoning called PATHSEEKER. This solution takes the form of a reasoning agent that can interactively perceive and navigate pathways using a web-like engine, along with flexible reasoning in each step.

Subgraph Navigation-based Graph Browsing Inspired by how humans browse web networks, PATHSEEKER allows the language agent to flexibly explore a vast graph database by observing subgraphs at each step, as shown in Figure 3. At step t, the language agent G takes an action step a_t based on problem \mathcal{E} (problem instructions) and previous observation-action trajectory $h_t = [o_1, a_1, \dots, o_{t-1}, a_{t-1}, o_t]$,

$$a_t = G(\mathcal{E}, h_t) \tag{4}$$

In addition to the global subgraph retriever Search_Subgraph, PATHSEEKER has access to an additional neighbor subgraph retriever, Neighbor_Subgraph(*line_id*, *query*, N), which retrieves an optimal connected subgraph of target size from the multi-hop neighbors of a previously observed pathway step *line_id*.

$$Neighbor_Subgraph(line_id, query, N) = \underset{S \subseteq P_{id}, S \text{ is connected }, |S|=N}{\operatorname{argmax}} \sum_{i \in V : \cup E_S} \operatorname{score}(i, query)$$
(5)

Here, P_{id} represents the multi-hop neighbors of the triple with *line_id*. This allows PATHSEEKER to navigate the pathway graph database by either performing a global search or by exploring the multi-hop neighbors of an observed subgraph at each step. See Appendix for case A.7.

324 **Graph Encoding** In step t, the action taken by LLM agent get subgraph S_t from environment, and 325 the subgraph is encoded into text observation o_t as following: 326

$$\hat{S}_t = \text{DFSOrder}(\text{RemoveSeen}(S_t, [S_1, \dots, S_{t-1}]))$$

327

339

340 341 342

343

344

345

346

347 348

349

351

(6) $o_t = \text{TripleToOrderedText}(\hat{S}_t, \text{TotalNum}([S_1, \dots, S_{t-1}]))$

Function RemoveSeen eliminates triples from the t-th turn's subgraph that have been observed in 330 previous turns, ensuring that each triple appears in the LLM's observations only once when first 331 retrieved. This approach enhances content length efficiency and encourages the LLM to understand 332 the whole navigation history rather than focusing solely on the most recent turn.

333 The function TripleToOrderedText convert ordered subgraph \hat{S}_t into text in the following format: 334 Line ID) Head | Tail | Relation and Biological Process. These global line IDs indicate the order of 335 each triple across all turns, providing a unique reference for the LLM agent during local searches or 336 reasoning. For the t-th turn's subgraph S_t , the ID starts at the total number of unique triples seen in 337 previous history, given by TotalNum($[S_1, \ldots, S_{t-1}]$). 338

Final Reasoning As graph data browsing finishes, the final reasoning is conducted based on all the navigation history:

$$a_r = G(\mathcal{E}_r, [o_1, \dots, o_T])$$

Graph Navigation Capacity The combination of global and local subgraph retrieval APIs empowers LLM agents to explore the entire network flexibly and efficiently. It allows the LLM to guide its exploration by adjusting both keywords and the root of the local subgraph, depending on the intermediate reasoning, offering stronger expressiveness than navigation methods like BFS, DFS, and various retrieval methods.

5 **EXPERIMENT**

350 5.1 **BASELINE AND METRIC**

352 We evaluate the reasoning performance of LLMs on BioMaze in both the unaugmented step-by-step 353 reasoning and the pathway graph-augmented methods. We adopt reasoning method without graph 354 augmentation Chain-of-Thought (CoT) (Wei et al., 2022; Kojima et al., 2022), and methods with 355 pathway graph augmentation: Chain-of-Knowledge (CoK) (Li et al., 2023a), Think-of-Graph (ToG) (Sun et al., 2023), and G-Retriever (He et al., 2024). Details of baselines are in Appendix A.8. 356

357 For True/False tasks, we compute accuracy averaged across the True and False labels to account for 358 label imbalance in the dataset. For open-ended tasks, the LLM is used to evaluate the accuracy of 359 generated answers by comparing them to the ground truth and determining whether they are correct 360 or incorrect. In this study, we use the LLaMA3.1-405B model as the evaluator, with five in-context 361 examples. The performance of the evaluator is further analyzed in Appendix A.9.

- 362 363 5.2 MAIN RESULT
- 364

We evaluate PATHSEEKER and baseline methods on BioMaze, presenting results in Tables 2 and 3. The comparison covers task dimensions including signal source, additional conditions, and target. 366 The results lead to the following conclusions: 367

368 LLMs can perform biological system reasoning tasks. Despite the extreme difficulty of the tasks in BioMaze, LLMs still achieved strong results, especially in normal inquiry and natural condition 369 cases. The overall performance suggests that LLMs are capable of reasoning in many biological 370 research scenarios, effectively explaining and predicting phenomena within biological systems. 371

372 Question with perturbation query in BioMaze presents significant reasoning challenges for 373 LLMs. Specifically, LLMs struggle more with perturbed inquiry type settings than with normal 374 inquiry types in both True/False and open-ended formats. This suggests that reasoning about bio-375 logical pathways becomes more complex in intervention scenarios, where the events are less likely to align with common biological knowledge and require deductive reasoning to predict pathway 376 behavior. In contrast, questions set in normal scenarios are more likely to be answerable using 377 established biological knowledge about how typical pathways work.

Table 2: Accuracy (%) on BioMaze True/False tasks (50% corresponds to the random guessing baseline). For each method, the lowest result within each dimension is underlined to highlight the most challenging setting.

		Inqui	iry Type	Extra	Condition	Ir	vestigation Ta	arget
	w.t. Pathway Graph	Normal	Perturbed	Natural	Intervened	Single	Interaction	Function
GPT-3.5								
Viliana (0 Shot)		76.80	67.42	74.30	66.23	<u>68.90</u>	78.97	71.44
Viliana (2 Shot)	×	72.09	70.22	71.28	70.28	70.48	81.24	<u>67.15</u>
CoT (0 Shot)	r r	78.02	<u>65.45</u>	75.08	<u>64.35</u>	<u>68.45</u>	69.75	75.23
CoT (2 Shot)		77.03	<u>67.13</u>	73.65	<u>68.92</u>	<u>68.92</u>	79.26	71.85
ToG		74.57	69.66	74.17	68.04	70.03	73.67	73.80
CoK	/	77.47	68.54	73.09	72.95	67.92	80.56	73.86
G-Retriever	V	76.26	70.20	75.72	70.81	73.04	76.21	73.59
PATHSEEKER		78.85	74.44	77.63	74.36	78.01	81.66	<u>73.78</u>
LLaMA3 8B								
Viliana (0 Shot)		80.49	67.70	76.78	67.17	75.27	73.88	73.27
Viliana (2 Shot)	×	80.19	72.75	78.42	70.69	79.72	83.18	70.85
CoT (0 Shot)	^	75.07	67.13	72.04	68.66	73.15	80.15	66.33
CoT (2 Shot)		81.77	71.63	79.04	70.67	79.73	84.35	71.52
ToG		79.37	69.31	76.96	67.60	76.57	83.17	69.16
CoK	/	80.20	67.70	75.87	69.00	77.27	81.11	68.93
G-Retriever	V	80.59	72.29	81.17	70.06	80.97	82.29	73.53
PATHSEEKER		83.08	75.84	82.14	72.27	81.07	86.62	75.01

Table 3: Accuracy (%, evaluated by LLM) on BioMaze open-ended tasks. For each method, the lowest result within each dimension is underlined to highlight the most challenging setting.

		Inqui	iry Type	Extra	Condition	Ir	vestigation Ta	arget
	w.t. Pathway Graph	Normal	Perturbed	Natural	Intervened	Single	Interaction	Function
GPT-3.5 CoT (0 Shot) CoT (2 Shot)	×	76.60 82.67	<u>67.67</u> 73.66	72.93 79.66	$\frac{68.28}{72.69}$	73.20 83.28	$\frac{64.86}{63.51}$	71.50 75.73
ToG CoK G-Retriever PATHSEEKER	1	74.77 82.98 84.38 87.84	<u>65.27</u> <u>73.43</u> <u>72.84</u> <u>77.91</u>	70.81 80.41 80.78 83.65	<u>66.08</u> <u>70.93</u> <u>74.37</u> <u>78.85</u>	72.13 82.30 82.55 85.29	<u>62.16</u> <u>67.57</u> <u>70.40</u> <u>77.03</u>	68.60 75.73 76.92 80.74
LLaMA3 8B CoT (0 Shot) CoT (2 Shot)	×	82.37 80.55	<u>69.53</u> <u>67.91</u>	77.63 75.94	$\frac{69.16}{67.40}$	76.14 77.78	<u>62.16</u> 55.41	76.78 73.35
ToG CoK G-Retriever PATHSEEKER	1	84.80 80.55 82.62 84.50	73.49 70.70 72.10 76.51	80.64 77.82 77.21 80.64	73.13 68.28 75.92 78.41	82.68 78.43 80.71 83.01	74.32 64.86 72.53 78.38	75.73 74.14 75.65 <u>77.84</u>

Reasoning target brings diverse challenges for reasoning. The Investigation target presents varied difficulties, resulting in inconsistent performance across different backbone models and reasoning methods. Interestingly, the performance of True/False questions varies between GPT-3.5 and LLaMA3, likely due to differences in the knowledge underlying the two models. Additionally, open-ended questions about interactions are the most challenging, which differs from the True/False format. This may be due to the nature of open-ended questions, which have a broader possible answer space for questions about interaction.

Pathway augmentation can enhance reasoning in biological systems, especially for intervention cases. As shown in Tables 2 and 3, reasoning methods with pathway augmentation, especially PATHSEEKER, outperform non-augmented approaches. PATHSEEKER consistently exceeds
CoT across all question types and categories, regardless of the backbone model, highlighting the
value of integrating biological pathways to enhance reasoning in biological systems. Additionally,
PATHSEEKER outperforms other graph augmentation methods, demonstrating the effectiveness of
its subgraph-based navigation approach. Notably, it reduces the performance gap between natural
and intervened/perturbed groups, helping bridge the gap in causal reasoning for biological pathways.

- 432 5.3 ANALYSIS 433
- 434

450 451 452

453

454

455

456

457 458

461

5.3.1 TASK ANALYSIS

436 **Reasoning Difficulty with Steps** While LLMs excel at complex reasoning by breaking down ques-437 tions into basic steps for detailed deductive reasoning, it's widely recognized that the complexity 438 of reasoning is closely tied to the foundational steps needed for a task. To explore the relationship between task complexity and reasoning steps in BioMaze, we analyzed the reasoning steps for each 439 440 instance by prompting the LLaMA3.1-405B to explain their reasoning process based on the correct answer and pathway information. 441

442 Figure 4 shows the performance of Chain-of-Thought (CoT) reasoning. As the number of reasoning 443 steps increases, CoT performance steadily declines, indicating that reasoning difficulty rises with 444 a greater number of pathway steps. This finding supports our hypothesis that the challenges in 445 biological pathway reasoning are largely due to the complexity of the pathways involved.

446 Notably, PATHSEEKER's performance remains more consistent across different reasoning step 447 counts. This suggests that augmenting LLMs with biological pathway information can mitigate the 448 challenges of pathway reasoning, particularly when dealing with intricate intermediate processes. 449




Figure 4: Performance versus reasoning steps. LLMs face increasing difficulty in reasoning about 459 biological systems as task complexity rises and requires more reasoning steps. In contrast, pathway 460 augmentation significantly mitigates the drop of performance for tasks that involve more steps.

462 **Reasons for Failure Statistics** To illustrate the reasons why LLMs fail in biological pathway reason-463 ing, we analyze failed cases across various reasoning methods, including CoT and PATHSEEKER. 464 The failure reasons are classified into the following categories: (1) Unresolved Conclusion For 465 cases where the model fails to provide a definitive answer, indicating uncertainty or belief that the 466 answer is unknown. (2) Incomplete Answer When the response lacks essential details, such as 467 missing the requested effects or other key elements. (3) **Omission in Reasoning** For errors where 468 critical pathway steps in the question's biological process are left out, causing the final answer to 469 be incorrect. (4) Faulty in Reasoning When the reasoning path is correct, but there are significant 470 errors in deducing the events within that pathway. We manually classify 100 random samples from these error cases to approximate the overall error cases, with a professional biology Ph.D. student. 471

472 The results are shown in Figure 5. The results in Figure 5 show that in both True/False and open-473 ended tasks, the main error in CoT reasoning is faulty reasoning, where LLMs correctly identify the 474 biological pathway but misinterpret the events within it. Another key error is omission, where crit-475 ical steps or branches of the pathway are overlooked. This highlights the challenges LLMs face in 476 reasoning about biological pathways, due to both knowledge gaps and difficulties in deductive reasoning. PATHSEEKER significantly reduces faulty reasoning by providing pathway graphs, enabling 477 more accurate reasoning about biological events. However, omissions remain a predominant issue, 478 often due to limitations in the pathway database and oversights during browsing. Additionally, with 479 the availability of pathways, LLMs are less likely to fail in providing definitive answers, becoming 480 more confident in drawing conclusions. 481

482 Performance with Biological Domain Figure 6 presents a comparison of the performance of various reasoning methods across different biological domains in BioMaze. The results demonstrate 483 that the difficulty of each domain varies depending on the reasoning method used. Overall, PATH-484 SEEKER, when augmented with pathway information, consistently outperforms direct reasoning 485 across nearly all biological domains. The results of more backbones are in Appendix A.11.

492

493

494

495

504

505

506 507

508

509

510

511

512

513

514

515 516

517

518

519

521

522

523

524

525 526




Figure 5: Error analysis for CoT reasoning and reasoning with pathway augmentation (our method PATHSEEKER). The primary cause of errors in (CoT) reasoning for biological systems is due to both faulty reasoning and omissions in reasoning. When pathway augmentation is applied, omissions in reasoning become the predominant issue, but the rate of faulty reasoning is significantly reduced, thereby improving the overall reasoning accuracy of LLMs in biological systems.




Figure 6: GPT-3.5's performance across different biological domains in BioMaze. 5.4 METHOD ANALYSIS AND ABLATION STUDY

API Usage and Step Distribution We analyze PATHSEEKER's agent behavior by reviewing task steps and navigation API usage frequency. Tables 4 and 5 show that over half of the tasks are completed in six steps or fewer, while some take over ten steps which is possible due to lacking relevant pathway data. On average, the agent performs 1.5 global searches per task, suggesting multiple searches are often needed, and local navigation occurs more than three times per task, highlighting thorough subgraph exploration.

Table 4: Agent steps distribution (%) of PATH-SEEKER during task completion.

Table 5:	Average	API	usage	times	of	Path-
SEEKER	during tas	k cor	npletio	n.		

Local

3.40

3.26

Agent Steps	1-4	4-6	6-8	8-10	≥ 10		Global
True/False	14.35	42.26	20.97	9.68	12.74	True/False	e 1.51
Open-Ended	19.50	41.77	15.94	8.43	14.36	Open-Ende	ed 1.62

Ablation Study To assess the effectiveness of PATHSEEKER's components, we conduct ablation studies, with results for LLaMA3-8B shown in Table 6. The most impactful component is Final-Reaser; without it, the agent's answers suffer due to the long task history, disrupting reasoning and responses. The local search API is also critical, enabling efficient graph navigation. Lastly, the graph encoding method boosts performance, emphasizing the importance of encoding graph data for sequential language models.

Table 6: Ablation Study of PATHSEEKER.

	PATHSEEKER	w.o. RemoveSeen	w.o. DFSOrder	w.o. Local search	w.o. FinalReasoner
True/False	79.24	76.57	77.4	77.29	75.33
Open-Ended	79.97	77.52	77.02	76.27	71.86

6 CONCLUSION

534 In this study, we introduce BioMaze, a benchmark designed to evaluate LLMs' ability to understand 535 and reason about biological pathways by predicting the effects of natural and synthetic interven-536 tions, like mutations and infections, on downstream targets. Extensive evaluations using BioMaze, incorporating advanced methods like CoT and pathway graph-augmented approaches, show that LLMs struggle with understanding pathway mechanisms with intervention. We also propose PATH-538 SEEKER, a novel LLM agent that uses interactive subgraph exploration to enhance reasoning in biological pathways by leveraging pathway graphs as structured blueprints.

540 REFERENCES 541

547

548

556

558

559

563

564

- Microsoft Research AI4Science and Microsoft Azure Quantum. The impact of large language mod-542 els on scientific discovery: a preliminary study using gpt-4. arXiv preprint arXiv:2311.07361, 543 2023. 544
- Muhammad Azam, Yibo Chen, Micheal Olaolu Arowolo, Haowang Liu, Mihail Popescu, and Dong 546 Xu. A comprehensive evaluation of large language models in mining gene relations and pathway knowledge. Quantitative Biology, 2024.
- Maciej Besta, Nils Blach, Ales Kubicek, Robert Gerstenberger, Michal Podstawski, Lukas Gian-549 inazzi, Joanna Gajda, Tomasz Lehmann, Hubert Niewiadomski, Piotr Nyczyk, et al. Graph of 550 thoughts: Solving elaborate problems with large language models. In Proceedings of the AAAI 551 Conference on Artificial Intelligence, volume 38, pp. 17682–17690, 2024. 552
- 553 Sitao Cheng, Ziyuan Zhuang, Yong Xu, Fangkai Yang, Chaoyun Zhang, Xiaoting Qin, Xiang Huang, 554 Ling Chen, Qingwei Lin, Dongmei Zhang, et al. Call me when necessary: Llms can efficiently and faithfully reason over structured environments. arXiv preprint arXiv:2403.08593, 2024. 555
 - Abhimanyu Dubey, Abhinav Jauhri, Abhinav Pandey, Abhishek Kadian, Ahmad Al-Dahle, Aiesha Letman, Akhil Mathur, Alan Schelten, Amy Yang, Angela Fan, et al. The llama 3 herd of models. arXiv preprint arXiv:2407.21783, 2024.
- 560 Darren Edge, Ha Trinh, Newman Cheng, Joshua Bradley, Alex Chao, Apurva Mody, Steven Truitt, and Jonathan Larson. From local to global: A graph rag approach to query-focused summariza-561 tion. arXiv preprint arXiv:2404.16130, 2024. 562
 - Bahare Fatemi, Jonathan Halcrow, and Bryan Perozzi. Talk like a graph: Encoding graphs for large language models. arXiv preprint arXiv:2310.04560, 2023.
- 566 Tomas Hayes, Roshan Rao, Halil Akin, Nicholas J Sofroniew, Deniz Oktay, Zeming Lin, Robert Verkuil, Vincent Q Tran, Jonathan Deaton, Marius Wiggert, et al. Simulating 500 million years 567 of evolution with a language model. *bioRxiv*, pp. 2024–07, 2024. 568
- 569 Xiaoxin He, Xavier Bresson, Thomas Laurent, Adam Perold, Yann LeCun, and Bryan Hooi. Har-570 nessing explanations: Llm-to-lm interpreter for enhanced text-attributed graph representation 571 learning. arXiv preprint arXiv:2305.19523, 2023. 572
- Xiaoxin He, Yijun Tian, Yifei Sun, Nitesh V Chawla, Thomas Laurent, Yann LeCun, Xavier Bres-573 son, and Bryan Hooi. G-retriever: Retrieval-augmented generation for textual graph understand-574 ing and question answering. arXiv preprint arXiv:2402.07630, 2024. 575
- 576 Yufei He and Bryan Hooi. Unigraph: Learning a cross-domain graph foundation model from natural 577 language. arXiv preprint arXiv:2402.13630, 2024. 578
- 579 Chinmay Hegde, Piotr Indyk, and Ludwig Schmidt. A nearly-linear time framework for graphstructured sparsity. In International Conference on Machine Learning, pp. 928–937. PMLR, 580 2015. 581
- 582 Ramtin Hosseini, Siyang Zhang, and Pengtao Xie. Text2protein: A generative model for designated 583 protein design on given description. 2024. 584
- Jinhao Jiang, Kun Zhou, Zican Dong, Keming Ye, Wayne Xin Zhao, and Ji-Rong Wen. Structgpt: 585 A general framework for large language model to reason over structured data. arXiv preprint 586 arXiv:2305.09645, 2023. 587
- 588 Bowen Jin, Chulin Xie, Jiawei Zhang, Kashob Kumar Roy, Yu Zhang, Suhang Wang, Yu Meng, and 589 Jiawei Han. Graph chain-of-thought: Augmenting large language models by reasoning on graphs. 590 arXiv preprint arXiv:2404.07103, 2024. 591
- Di Jin, Eileen Pan, Nassim Oufattole, Wei-Hung Weng, Hanyi Fang, and Peter Szolovits. What dis-592 ease does this patient have? a large-scale open domain question answering dataset from medical 593 exams. Applied Sciences, 11(14):6421, 2021.

595

dataset for biomedical research question answering. arXiv preprint arXiv:1909.06146, 2019. 596 Oiao Jin, Zifeng Wang, Charalampos S Floudas, Fangyuan Chen, Changlin Gong, Dara Bracken-597 Clarke, Elisabetta Xue, Yifan Yang, Jimeng Sun, and Zhiyong Lu. Matching patients to clinical 598 trials with large language models. ArXiv, 2023. 600 Minoru Kanehisa and Susumu Goto. Kegg: kyoto encyclopedia of genes and genomes. Nucleic 601 acids research, 28(1):27-30, 2000. 602 Takeshi Kojima, Shixiang Shane Gu, Machel Reid, Yutaka Matsuo, and Yusuke Iwasawa. Large 603 language models are zero-shot reasoners. Advances in neural information processing systems, 604 35:22199-22213, 2022. 605 606 Anastasia Krithara, Anastasios Nentidis, Konstantinos Bougiatiotis, and Georgios Paliouras. 607 Bioasq-qa: A manually curated corpus for biomedical question answering. Scientific Data, 10 608 (1):170, 2023. 609 Shilong Li, Yancheng He, Hangyu Guo, Xingyuan Bu, Ge Bai, Jie Liu, Jiaheng Liu, Xingwei Qu, 610 Yangguang Li, Wanli Ouyang, et al. Graphreader: Building graph-based agent to enhance long-611 context abilities of large language models. arXiv preprint arXiv:2406.14550, 2024. 612 613 Xingxuan Li, Ruochen Zhao, Yew Ken Chia, Bosheng Ding, Shafiq Joty, Soujanya Poria, and Li-614 dong Bing. Chain-of-knowledge: Grounding large language models via dynamic knowledge adapting over heterogeneous sources. arXiv preprint arXiv:2305.13269, 2023a. 615 616 Yanjing Li, Hannan Xu, Haiteng Zhao, Hongyu Guo, and Shengchao Liu. Chatpathway: Conver-617 sational large language models for biology pathway detection. In NeurIPS 2023 AI for Science 618 Workshop, 2023b. 619 620 Hao Liu, Jiarui Feng, Lecheng Kong, Ningyue Liang, Dacheng Tao, Yixin Chen, and Muhan Zhang. One for all: Towards training one graph model for all classification tasks. arXiv preprint 621 arXiv:2310.00149, 2023a. 622 623 Shengchao Liu, Weili Nie, Chengpeng Wang, Jiarui Lu, Zhuoran Qiao, Ling Liu, Jian Tang, 624 Chaowei Xiao, and Animashree Anandkumar. Multi-modal molecule structure-text model for 625 text-based retrieval and editing. Nature Machine Intelligence, 5(12):1447–1457, 2023b. 626 Shengchao Liu, Jiongxiao Wang, Yijin Yang, Chengpeng Wang, Ling Liu, Hongyu Guo, and 627 Chaowei Xiao. Chatgpt-powered conversational drug editing using retrieval and domain feed-628 back. arXiv preprint arXiv:2305.18090, 2023c. 629 630 Pan Lu, Swaroop Mishra, Tanglin Xia, Liang Qiu, Kai-Wei Chang, Song-Chun Zhu, Oyvind Tafjord, 631 Peter Clark, and Ashwin Kalyan. Learn to explain: Multimodal reasoning via thought chains for 632 science question answering. Advances in Neural Information Processing Systems, 35:2507–2521, 633 2022. 634 Andres M. Bran, Sam Cox, Oliver Schilter, Carlo Baldassari, Andrew D White, and Philippe 635 Schwaller. Augmenting large language models with chemistry tools. Nature Machine Intelli-636 gence, pp. 1-11, 2024. 637 638 Ali Madani, Bryan McCann, Nikhil Naik, Nitish Shirish Keskar, Namrata Anand, Raphael R Eguchi,

Qiao Jin, Bhuwan Dhingra, Zhengping Liu, William W Cohen, and Xinghua Lu. Pubmedqa: A

- Po-Ssu Huang, and Richard Socher. Progen: Language modeling for protein generation. *arXiv* preprint arXiv:2004.03497, 2020.
 Ankit Pal, Logesh Kumar Umapathi, and Malaikannan Sankarasubbu. Medmcqa: A large-scale
- Ankit Pal, Logesh Kumar Umapathi, and Malaikannan Sankarasubbu. Medmcqa: A large-scale
 multi-subject multi-choice dataset for medical domain question answering. In *Conference on health, inference, and learning*, pp. 248–260. PMLR, 2022.
- Gilchan Park, Byung-Jun Yoon, Xihaier Luo, Vanessa López-Marrero, Patrick Johnstone, Shinjae
 Yoo, and Francis J Alexander. Comparative performance evaluation of large language models
 for extracting molecular interactions and pathway knowledge. *arXiv preprint arXiv:2307.08813*, 2023.

- Junkil Park, Youhan Lee, and Jihan Kim. Multi-modal conditioning for metal-organic frameworks generation using 3d modeling techniques. 2024.
- Noah Shinn, Federico Cassano, Ashwin Gopinath, Karthik R Narasimhan, and Shunyu Yao. Re flexion: Language agents with verbal reinforcement learning. In *Thirty-seventh Conference on Neural Information Processing Systems*, 2023.
- Karan Singhal, Shekoofeh Azizi, Tao Tu, S Sara Mahdavi, Jason Wei, Hyung Won Chung, Nathan
 Scales, Ajay Tanwani, Heather Cole-Lewis, Stephen Pfohl, et al. Large language models encode
 clinical knowledge. *Nature*, 620(7972):172–180, 2023.
- Jiashuo Sun, Chengjin Xu, Lumingyuan Tang, Saizhuo Wang, Chen Lin, Yeyun Gong, Lionel Ni, Heung-Yeung Shum, and Jian Guo. Think-on-graph: Deep and responsible reasoning of large language model on knowledge graph. In *The Twelfth International Conference on Learning Representations*, 2023.
- Jiabin Tang, Yuhao Yang, Wei Wei, Lei Shi, Lixin Su, Suqi Cheng, Dawei Yin, and Chao Huang.
 Graphgpt: Graph instruction tuning for large language models. In *Proceedings of the 47th International ACM SIGIR Conference on Research and Development in Information Retrieval*, pp. 491–500, 2024.
- Giorgio Valentini, Dario Malchiodi, Jessica Gliozzo, Marco Mesiti, Mauricio Soto-Gomez, Alberto
 Cabri, Justin Reese, Elena Casiraghi, and Peter N Robinson. The promises of large language
 models for protein design and modeling. *Frontiers in Bioinformatics*, 3:1304099, 2023.
- David Vilares and Carlos Gómez-Rodríguez. Head-qa: A healthcare dataset for complex reasoning.
 arXiv preprint arXiv:1906.04701, 2019.
- Heng Wang, Shangbin Feng, Tianxing He, Zhaoxuan Tan, Xiaochuang Han, and Yulia Tsvetkov.
 Can language models solve graph problems in natural language? *Advances in Neural Information Processing Systems*, 36, 2024.
- Kuezhi Wang, Jason Wei, Dale Schuurmans, Quoc V Le, Ed H Chi, Sharan Narang, Aakanksha Chowdhery, and Denny Zhou. Self-consistency improves chain of thought reasoning in language models. In *The Eleventh International Conference on Learning Representations*, 2022.
- Jason Wei, Xuezhi Wang, Dale Schuurmans, Maarten Bosma, Fei Xia, Ed Chi, Quoc V Le, Denny
 Zhou, et al. Chain-of-thought prompting elicits reasoning in large language models. *Advances in neural information processing systems*, 35:24824–24837, 2022.
- Johannes Welbl, Pontus Stenetorp, and Sebastian Riedel. Constructing datasets for multi-hop read ing comprehension across documents. *Transactions of the Association for Computational Lin- guistics*, 6:287–302, 2018.
- Shunyu Yao, Jeffrey Zhao, Dian Yu, Nan Du, Izhak Shafran, Karthik Narasimhan, and Yuan Cao.
 React: Synergizing reasoning and acting in language models, 2023.
- Ruosong Ye, Caiqi Zhang, Runhui Wang, Shuyuan Xu, Yongfeng Zhang, et al. Natural language is all a graph needs. *arXiv preprint arXiv:2308.07134*, 4(5):7, 2023.
- Longhui Yu, Weisen Jiang, Han Shi, Jincheng Yu, Zhengying Liu, Yu Zhang, James T Kwok, Zhenguo Li, Adrian Weller, and Weiyang Liu. Metamath: Bootstrap your own mathematical questions for large language models. *arXiv preprint arXiv:2309.12284*, 2023.
- Haiteng Zhao, Shengchao Liu, Ma Chang, Hannan Xu, Jie Fu, Zhihong Deng, Lingpeng Kong, and
 Qi Liu. Gimlet: A unified graph-text model for instruction-based molecule zero-shot learning.
 Advances in Neural Information Processing Systems, 36:5850–5887, 2023.
- Haiteng Zhao, Chang Ma, Guoyin Wang, Jing Su, Lingpeng Kong, Jingjing Xu, Zhi-Hong Deng, and Hongxia Yang. Empowering large language model agents through action learning. *arXiv* preprint arXiv:2402.15809, 2024.
- Zhiling Zheng, Ali H Alawadhi, Saumil Chheda, S Ephraim Neumann, Nakul Rampal, Shengchao Liu, Ha L Nguyen, Yen-hsu Lin, Zichao Rong, J Ilja Siepmann, et al. Shaping the water-harvesting behavior of metal–organic frameworks aided by fine-tuned gpt models. *Journal of the American Chemical Society*, 145(51):28284–28295, 2023.

702 A APPENDIX

704 A.1 DATASET CASE ILLUSTRATION

706 Dimension 1: Inquiry Type

707 708 Category 1: Normal Source

"Question": "AMP-activated protein kinase (AMPK) is a metabolic fuel gauge that senses changes
in the intracellular AMP/ATP ratio. Recent evidence suggests that AMPK plays a role in the therapeutic benefits of metformin, thiazolidinediones, and exercise in the management of type 2 diabetes and associated metabolic disorders. AMPK controls the expression of genes involved in energy metabolism in mouse skeletal muscle by working together with another metabolic sensor, the
NAD+-dependent type III deacetylase SIRT1. Does AMPK enhance SIRT1 activity by decreasing cellular NAD+ levels?",

716 "Answer": "No"

"Question": "Adrenergic receptor signaling in adipocytes controls the hydrolysis of triglycerides and is involved in brown adipocyte thermogenesis and energy consumption. Do beta-adrenergic receptors activate a network of signaling pathways that include cAMP-dependent protein kinase and members of the mitogen-activated protein kinase family?",

721 "Answer": "Yes"

"Question": "Enteropathogenic Escherichia coli (EPEC) is a human pathogen that colonizes the gut mucosa and causes diarrheal diseases. EPEC uses a type III secretion system (T3SS) to deliver effectors into host cells, which repress innate immune responses and infiltration of immune cells.
One of these effectors is NleF. What is the effect of NleF on caspase-4 activity in intestinal epithelial cells (IECs) infected with EPEC?",

"Answer": "NleF inhibits the proteolytic activity of caspase-4 in IECs infected with EPEC."

"Question": "Epithelial-mesenchymal transition (EMT) of tubular epithelial cells is a key event in renal interstitial fibrosis and the progression of chronic kidney disease (CKD). Apelin is a regulatory peptide involved in the regulation of normal renal hemodynamics and tubular functions. To examine the effects of apelin on transforming growth factor-beta1 (TGF-beta1)-induced EMT in HK-2 cells, cells were co-treated with apelin and TGF-beta1. What is the effect of apelin on TGF-beta1-mediated upregulation of alpha-smooth muscle actin (alpha-SMA) and downregulation of E-cadherin in HK-2 cells?",

- "Answer": "Apelin inhibits TGF-beta1-mediated upregulation of alpha-smooth muscle actin (alpha-SMA) and downregulation of E-cadherin in HK-2 cells."
- 738 739 Category 2: Perturbed Source

"Question": "To investigate the role of Dectin-1 in the innate response to mycobacteria, an in vitro
system was used to measure IL-12p40 production in splenic dendritic cells (SpDC) exposed to live
Mycobacterium tuberculosis bacilli. Does pharmacologic inhibition of spleen tyrosine kinase (Syk)
reduce the IL-12p40 response induced by M. tuberculosis?",

744 "Answer": "Yes"

745 "Question": "Deficiency of GDP-Man:Man1GlcNAc2-PP-dolichol mannosyltransferase (hALG2) 746 causes a new type of congenital disorder of glycosylation (CDG) called CDG-Ii. A patient with 747 CDG-Ii showed symptoms such as mental retardation, seizures, coloboma of the iris, hypomyelina-748 tion, hepatomegaly, and coagulation abnormalities. Skin fibroblasts from the patient exhibited an 749 accumulation of Man1GlcNAc2-PP-dolichol and Man2GlcNAc2-PP-dolichol. The patient's fibrob-750 last extracts were incubated with Man1GlcNAc2-PP-dolichol and GDP-mannose, and it was found 751 that the mannosyltransferase activity elongating Man1GlcNAc2-PP-dolichol was severely reduced. 752 The yeast ALG2 sequence was used to identify the human ortholog, and genetic analysis revealed 753 that the patient had a single nucleotide deletion and a single nucleotide substitution in the human ALG2 gene. Was the expression of mutant hALG2 cDNA able to restore the mannosyltransferase 754 activity and the biosynthesis of dolichol-linked oligosaccharides in both patient fibroblasts and yeast 755 cells?",

756 "Answer": "No"

"Question": "Advanced glycation end products (AGEs) play a significant role in diabetic complications by activating various signaling pathways. One of the key pathways involved is the transforming growth factor (TGF)-beta signaling pathway, which regulates Smad proteins. To understand the
role of Smad signaling in diabetic complications, researchers have investigated the effect of AGEs
on Smad activation and collagen synthesis. What is the effect of overexpressing Smad7 on AGEinduced Smad activation and collagen synthesis?",

"Answer": "Overexpression of Smad7 prevents AGE-induced Smad activation and collagen synthesis."

"Question": "Aggregation of amyloid-beta (Abeta) and Tau protein are hallmarks of Alzheimer's disease (AD). According to the Abeta-cascade hypothesis, Abeta is considered toxic for neurons and Tau is a downstream target of Abeta. In differentiated primary hippocampal neurons, the effect of exposure to Abeta oligomers on the phosphorylation of Tau in dendritic regions was investigated.
What is the effect of exposure to Abeta oligomers on the phosphorylation of Tau in dendritic regions?",

"Answer": "Exposure to Abeta oligomers leads to elevated phosphorylation of Tau at certain sitesdiagnostic of AD-Tau in dendritic regions."

774 Dimension 2: Extra Condition

776 Category 1: Natural Condition

"Question": "The expression and function of ENaC and Na,K-ATPase on the cell surface are tightly controlled by a complex regulatory network. Does aldosterone acutely regulate the expression of elements in this regulatory network that control the cell-surface localization and function of ENaC and Na,K-ATPase?",

781782 "Answer": "Yes"

"Question": "Alveolar macrophages (AM) play a central role in initiating and resolving lung inflammation, but the integration of these opposing functions is not well understood. Cholesterol
25-hydroxylase (CH25H) is highly expressed in AMs and is responsible for the production of 25hydroxycholesterol (25HC), which activates the anti-inflammatory nuclear receptor liver X receptor
(LXR). Is CH25H required for LXR-dependent promotion of AM lipid overload?",

788 "Answer": "No"

"Question": "To investigate the role of CSS3 in CS production, researchers overexpressed CSS3 in HeLa cells and measured the resulting CS levels. Does overexpressing CSS3 increase the amount of CS in HeLa cells?",

"Answer": "Overexpressing CSS3 increases the amount of CS in HeLa cells."

"Question": "Chronic activation of Wnt/beta-catenin signaling is found in various human malignan cies, including melanoma, colorectal, and hepatocellular carcinomas. What is the effect of HCMV
 infection on beta-catenin stabilization and signaling in cells?",

"Answer": "HCMV infection significantly increases beta-catenin stabilization and signaling in cells,
 which is mediated to a large extent by expression of US28."

Category 2: Intervened Condition

"Question": "The Bordetella adenylate cyclase toxin-hemolysin (CyaA) has multiple activities. In
CD11b+ J774A.1 monocytes, does the CyaA-AC-toxoid, which is unable to generate cAMP, promote a faster, transient elevation of [Ca2+]i compared to intact CyaA?",

804 "Answer": "Yes"

"Question": "Dos/Gab family scaffolding adapters, including Gab1 and Gab2, are known to bind signal relay molecules and play a role in signal transduction. While mice lacking Gab1 die during embryogenesis, Gab2-/- mice are viable and generally healthy. However, the response of Gab2-/- mast cells to stimulation of the high affinity immunoglobulin-epsilon (IgE) receptor Fc(epsilon)RI

is defective. Are the responses of mast cells in Gab2-/- mice enhanced when stimulated by the high affinity immunoglobulin-epsilon (IgE) receptor Fc(epsilon)RI?",

813 "Answer": "No"

"Question": "Stromal cell-derived factor 1 alpha (SDF-1alpha) is a chemotactic factor for T lymphocytes and binds to the G-protein-coupled receptor CXCR4. What is the role of LIM kinase 1 (LIMK1) in the chemotaxis of T lymphocytes induced by SDF-1alpha?",

"Answer": "LIMK1 phosphorylates cofilin and regulates actin reorganization, playing a critical role in SDF-1alpha-induced chemotaxis of T lymphocytes."

"Question": "The CXC chemokine stromal cell-derived factor-1alpha (SDF-1) binds to CXCR4, a seven-transmembrane G protein-coupled receptor that plays a critical role in many physiological processes, including cell migration and cell fate decisions. CXCR4 is also implicated in various pathological conditions, such as metastatic spread and human immunodeficiency virus infection. In the context of SDF-1-induced cell migration in CXCR4-expressing cells, what is the role of Galpha(13) in the activation of Rho by CXCR4?",

"Answer": "Galpha(13) mediates the activation of Rho by CXCR4."

827 Dimension 3: Investigation Target

828 829 Category 1: Single Component as Target

"Question": "Advanced glycation end product (AGE) activation of the signal-transducing receptor
for AGE (RAGE) has been linked to a proinflammatory phenotypic change within cells. Will human
serum albumin modified with N(epsilon)-(carboxymethyl)lysine (CML) inhibit nuclear factor (NF)kappaB-driven reporter gene expression in human monocytic THP-1 cells?",

834 "Answer": "No"

"Question": "Although the molecular mechanisms of hepatitis C virus (HCV) pathogenesis are not fully understood, the NS5A nonstructural protein of HCV has been found to interact with the growth factor receptor-bound protein 2 (Grb2) adaptor protein. To investigate the effects of NS5A on cellular signaling pathways, HeLa cells were stably expressing NS5A and were tested for their response to exogenous epidermal growth factor. Will HeLa cells stably expressing NS5A be refractory to ERK1/2 phosphorylation induced by exogenous epidermal growth factor?",

841 "Answer": "Yes"

"Question": "Enteropathogenic Escherichia coli (EPEC) and other related pathogens can trigger
an early apoptotic response in host cells through the secretion of various effectors, including those
from the type III secretion system. However, EPEC-infected cells do not typically progress to late
apoptotic stages. What is the effect of NleH effectors, which are homologs of the Shigella effector
kinase OspG, on caspase-3 activation during EPEC infection?",

- 848 "Answer": "NleH effectors inhibit caspase-3 activation during EPEC infection."
- "Question": "Epithelial-mesenchymal transition (EMT) of tubular epithelial cells is a key event in renal interstitial fibrosis and the progression of chronic kidney disease (CKD). Apelin is a regulatory peptide involved in the regulation of normal renal hemodynamics and tubular functions. To examine the inhibitory effects of apelin on transforming growth factor-beta1 (TGF-beta1)-induced EMT in HK-2 cells, cells were co-treated with apelin and TGF-beta1. What is the effect of apelin on TGF-beta1-mediated upregulation of alpha-smooth muscle actin (alpha-SMA) and downregulation of E-cadherin in HK-2 cells?",
- 856 "Answer": "Apelin inhibits TGF-beta1-mediated upregulation of alpha-smooth muscle actin (alpha857 SMA) and downregulation of E-cadherin in HK-2 cells."

Category 2: Components Interaction as Target

"Question": "Nucleotide-binding leucine-rich repeat-containing proteins, or NOD-like receptors
(NLRs), are intracellular innate immune sensors that can regulate several signaling pathways, including MyD88- and TRIF-dependent pathways. NLRP12 is a member of the NLR family that
can assemble into multimeric protein complexes known as inflammasomes. During infection with

Salmonella enterica serovar Typhimurium, does NLRP12 act as a negative regulator of the NFkap paB and MAPK signaling pathways?",

867 "Answer": "Yes"

"Question": "Pathogenic bacteria of the genus Yersinia employ a type III secretion system to inject bacterial effector proteins directly into the host cytosol. One of these effectors, the Yersinia
serine/threonine protein kinase YpkA, is an essential virulence determinant involved in host actin
cytoskeletal rearrangements and in inhibition of phagocytosis. Will Y. pseudotuberculosis expressing wild-type YpkA enhance Galphaq-mediated signaling pathways?",

873 "Answer": "No"

"Question": "Kaposi's sarcoma-associated herpesvirus (KSHV) has an immune evasion gene, K5.
What is the effect of K5-mediated ubiquitylation on NKG2D ligands MHC class I-related chain A (MICA) and NK cell-mediated cytotoxicity?",

"Answer": "K5-mediated ubiquitylation signals internalization but not degradation of MICA and causes a potent reduction in NK cell-mediated cytotoxicity."

"Question": "Measles virus infection is characterized by virus-induced immune suppression that
creates susceptibility to opportunistic infections, and it has been found that measles virus can inhibit
cytokine responses by direct interference with host STAT protein-dependent signaling systems. The
measles V protein plays a role in this interference, but how does the measles V protein specifically
affect STAT protein-dependent signaling systems?",

⁸⁸⁵ "Answer": "The measles V protein interferes with STAT protein-dependent signaling systems by causing a defect in IFN-induced STAT nuclear accumulation."

Category 3: Function as Target

"Question": "The dysfunction of mitochondria has long been recognized as a key component in
the progression of Parkinson's disease (PD). Can dysfunctional mitochondria lead to dysregulation
of calcium homeostasis and raised mean intracellular calcium concentration in dopaminergic neurons?",

893 "Answer": "Yes"

"Question": "The gut epithelium self-renews every several days, providing an important innate defense system that limits bacterial colonization. However, Shigella efficiently colonizes the intestinal epithelium. Is the cell-cycle arrest caused by Shigella infection in HeLa cells independent of IpaB and Mad2L2?",

"Answer": "No"

"Question": "Enterohemorrhagic Escherichia coli (EHEC) is a diarrheagenic pathogen that employs a type III secretion system (T3SS) to translocate 50 effector proteins, which allow bacterial colonization and subversion of immune responses and disease progression. One of these effector proteins is EspW, which is found in various EHEC strains. What is the effect of deleting espW on cell morphology during EHEC infection?",

- "Answer": "Infection of Swiss cells with an EHEC espW deletion mutant induces a cell shrinkage
 phenotype."
- "Question": "Enteropathogenic and enterohaemorrhagic Escherichia coli (EPEC and EHEC) are
 food-borne pathogens that cause severe diarrhoeal disease in humans. Citrobacter rodentium is a
 related mouse pathogen that serves as a small animal model for EPEC and EHEC infections. What
 is the effect of an Non-LEE-encoded effector A (NleA) protein variant with greatly diminished
 interaction with all Sec24 paralogues on virulence in the mouse infection model?",

"Answer": "An NleA protein variant with greatly diminished interaction with all Sec24 paralogues does not confer virulence in the mouse infection model."

- 915
- 916
- 917

918 A.2 FAILURE REASON CATEGORY CASES

919 920

935

936 937

938

939

940

941

942

943

944 945

946

947

948

949

950

951

952 953

954

955

956

957

958

959

960

961

962

963

We classify the error reason of biological pathway reasoning into four types: (1) **Unresolved Con**clusion For cases where the model fails to provide a definitive answer, indicating uncertainty or belief that the answer is unknown. (2) **Incomplete Answer** When the response lacks essential details, such as missing the requested effects or other key elements. (3) **Omission in Reasoning** For errors where critical pathway steps in the question's biological process are left out, causing the final answer to be incorrect. (4) **Faulty in Reasoning** When the reasoning path is correct, but there are significant errors in deducing the events within that pathway.

In this subsection, we provide examples of each failure reason type. The 'Question' and 'Answer' represent the input question and its labeled correct answer. The 'Wrong Answer by Model' refers to the incorrect response generated by the model. Additionally, we include a 'Reference Reasoning Process', which outlines the reasoning process leading to the correct final answer by LLaMA3.1 405B. This helps readers understand how errors occur during the reasoning process.

For the error types 'Omission in Reasoning' and 'Faulty Reasoning,' we present cases for both CoT and PathSeeker individually. These examples demonstrate how LLM reasoning fails either on its own or when augmented with a pathway graph.

Category 1: Unresolved Conclusion

"Question": "A large fraction of pediatric pre-B acute lymphoblastoid leukemias (ALL) consistently contain a t(1;19) chromosomal translocation, resulting in the production of a chimeric transcription factor containing the N-terminal transactivation domain of E2A fused to the C-terminal DNA-binding homeodomain of Pbx1. What is the effect of the E2A-Pbx1 fusion protein on the expression of the novel WNT gene, WNT-16, in pre-B ALL cells?", "Answer": "The E2A-Pbx1 fusion protein activates the expression of WNT-16 in pre-B ALL cells.",

"Wrong Answer by Model": "The E2A-Pbx1 fusion protein in pediatric pre-B acute lymphoblastic leukemias (ALL) with the t(1;19) chromosomal translocation is known to have oncogenic properties and can affect gene expression. In the case of the novel WNT gene, WNT-16, the E2A-Pbx1 fusion protein may have an effect on its expression in pre-B ALL cells. However, the specific effect of the fusion protein on WNT-16 expression would depend on the regulatory elements present in the WNT-16 gene and the transcriptional activity of the fusion protein. Further investigation would be needed to determine the exact effect of the E2A-Pbx1 fusion protein on WNT-16 expression in pre-B ALL cells.",

.....

"Reference Reasoning Process": "To determine the effect of the E2A-Pbx1 fusion protein on the expression of the novel WNT gene, WNT-16, in pre-B ALL cells, we can analyze the provided pathways for transcriptional regulation. The pathways indicate that both E2A (6929) and Pbx1 are transcription factors and that their fusion can lead to transcriptional activation of target genes.

Pathways 0 and 13 demonstrate that the E2A-Pbx1 fusion protein can cause the expression of WNT-16. The fusion of E2A and Pbx1 results in a chimeric transcription factor that retains the transactivation domain of E2A and the DNA-binding homeodomain of Pbx1.

Considering this information, it can be inferred that the E2A-Pbx1 fusion protein leads to increased expression of the novel WNT gene, WNT-16, in pre-B ALL cells. The fusion of E2A and Pbx1 results in a transcription factor that activates the expression of WNT-16, potentially contributing to the development or progression of pre-B ALL.

964 965 966

967

968

Figure 7: The Unresolved Conclusion error occurs when the model cannot provide a definitive answer, indicating uncertainty or the belief that the answer is unknown. In this case, the model is unable to determine the specific effect of the fusion protein on WNT-16 expression.

969 970 971

Category 2: Incomplete Answer

	"Question": "Continual efferocytic clearance of apoptotic cells (ACs) by macrophages crucial for injury resolution. The process of continual efferocytosis is enhanced by linkin the metabolism of engulfed cargo from initial efferocytic events to subsequent rounds. Ho
	is continual efferocytosis enhanced in macrophages?",
	"Answer": "Continual efferocytosis is enhanced in macrophages by the metabolism of apo
	totic cell-derived arginine and ornithine to putrescine by macrophage arginase 1 (Arg1) ar ornithine decarboxylase (ODC).",
	ormunine decarboxyrase (ODC).
	"Wrong Answer by Model": "Continual efferocytosis is enhanced in macrophages throug
	the process of metabolic reprogramming. When macrophages engulf apoptotic cells (AC
1	they not only clear the ACs but also metabolize the engulfed cargo. This metabolic repr
	gramming involves the activation of specific metabolic pathways, such as glycolysis a
	fatty acid oxidation, to generate energy and metabolites necessary for the efficient clearan
	of ACs. By linking the metabolism of engulfed cargo from initial efferocytic events to su
	sequent rounds, macrophages can sustain their energy requirements and maintain the hi
	phagocytic capacity needed for continual efferocytosis. This enhanced metabolic activi- allows macrophages to efficiently clear ACs and promote injury resolution.",
	anows macrophages to enciently creat Acs and promote injury resolution.
	"Reference Reasoning Process": "To determine how continual efferocytosis is enhanced
	macrophages, we can analyze the provided pathways for the key steps involved in efferocy
	clearance of apoptotic cells (ACs) and how they link to subsequent rounds.
	The process starts with the engulfment of apoptotic cells. This involves the recognition
	phosphatidylserine on the surface of apoptotic cells by receptors such as AGER (Pathw
	0). This recognition leads to the activation of signaling pathways, including the activation
	Rac family small GTPase 1 (RAC1), which is crucial for the engulfment process (Pathw
	1). Following engulfment, the metabolism of engulfed cargo plays a critical role in enhar
	ing continual efferocytosis. Specifically, the pathway involving the solute carrier family
	member 1 (SLC66A1) and the metabolism of L-Arginine (Pathway 6) leads to the produ
	tion of ornithine. Ornithine then binds to ARG1 (Pathway 7), leading to the producti
	of urea and more ornithine (Pathway 8). This process enhances continual efferocytosis
	providing the necessary components for subsequent rounds of efferocytic clearance.
	Moreover, the pathway involving the metabolism of ornithine to putrescine (Pathway 9) a
	then the activation of RAC1 by putrescine (Pathway 11) further supports the enhancement
	of continual efferocytosis. This is because RAC1 activation is crucial for the engulfme
	process, and its activation by putrescine ensures that the macrophage remains capable
	engulfing subsequent apoptotic cells. Therefore, based on the pathways provided, continual efferocytosis in macrophages is e
	hanced by the metabolism of engulfed cargo, specifically through the arginine and ornithi
	pathways, which ultimately lead to the activation of key signaling molecules such as RAG
	that are necessary for the efferocytic clearance of apoptotic cells.",
	,, ,, ,, ,, ,, ,, ,, ,

Figure 8: The Incomplete Answer error occurs when the response lacks essential details, such as missing the requested effects or other key elements. In this case, the model's response suggests that continual efferocytosis is enhanced in macrophages through metabolic reprogramming but fails to mention the metabolism of apoptotic cell-derived arginine and ornithine to putrescine, which is a key part of the labeled answer.

1017 1018

Category 3: Omission in Reasoning

1019 1020 Omission in Reasoning of CoT

"Question": "BAMBI (BMP and activin membrane-bound inhibitor) is known to negatively regulate the signaling activity of transforming growth factor-beta, activin, and BMP, and has been identified as a target of beta-catenin in colorectal and hepatocellular tumor cells. The canonical Wnt/beta-catenin pathway plays a crucial role in regulating embryogenesis

and tumorigenesis by promoting cell proliferation. Does BAMBI enhance or inhibit W promoted cell cycle progression?",
"Answer": "BAMBI increases Wnt-promoted cell cycle progression.",
"Wrong Answer by Model": "BAMBI inhibits Wnt-promoted cell cycle progression. T canonical Wnt/beta-catenin pathway promotes cell proliferation, and BAMBI has been id
tified as a target of beta-catenin. BAMBI negatively regulates the signaling activity
transforming growth factor-beta, activin, and BMP, which are involved in cell cycle r
ulation. Therefore, BAMBI acts as a negative regulator of the Wnt pathway and inhi
Wnt-promoted cell cycle progression.",
"Reference Reasoning Process": "To determine whether BAMBI enhances or inhibits W
promoted cell cycle progression, we need to analyze its interactions with key components
the Wnt signaling pathway.
From pathways 10, 11, and 12, we can see that BAMBI (BMP and activin membrane-bound publicity) interacts with LPBC FZD10, and DVI 1, which are all amounts of
inhibitor) interacts with LRP6, FZD10, and DVL1, which are all crucial components of Wnt signaling pathway. These interactions are described as "activation" and "binding/as
ciation," which suggests that BAMBI may be enhancing the activity of these component
However, it's also known that BAMBI is a negative regulator of the TGF-beta and B
signaling pathways, which can intersect with the Wnt signaling pathway.
Considering the complexity of these interactions and the multiple pathways involved,
need to look for more direct evidence of BAMBI's effect on Wnt-promoted cell cycle p
gression.
Given the information provided, it seems that BAMBI's interactions with the Wnt signal
pathway are more likely to be enhancing or modulating rather than inhibiting. Howe
without more direct evidence, it's difficult to make a definitive conclusion.
Therefore, based on the available information, it appears that BAMBI may enhance W
promoted cell cycle progression, but further research is needed to confirm this conclusio

Figure 9: Omission in Reasoning refers to errors where critical steps in the biological pathway described in the question are omitted, leading to an incorrect final answer. In this case, the model's reasoning process only considered that BAMBI has been identified as a target of beta-catenin but overlooked the pathway in which BAMBI interacts with LRP6, FZD10, and DVL1, all of which are crucial components of the Wnt signaling pathway. As a result, the reasoning led to an incorrect conclusion.

Omission in Reasoning of PathSeeker

1054

1061 1062 1063

1064 1065

1066

1067

1068

1069

1070

1071

1072

1074

1075

1076

"Question": "Angiotensin II (Ang II) is an octapeptide that plays a crucial role in the cardiovascular system, and its formation and degradation are tightly regulated. To investigate the role of mast cell proteases in Ang II production, ex vivo cultures of peritoneal cells from mouse strains lacking mast cell heparin or mouse mast cell protease 4 (mMCP-4) were used. What is the effect of heparin deficiency on the formation and degradation of Ang II in these peritoneal cell cultures?",

"Answer": "The formation and degradation of Ang II are strongly reduced in heparindeficient peritoneal cells.",

"Wrong Answer by Model": "Based on the provided pathways, the effect of heparin deficiency on the formation and degradation of Ang II in peritoneal cell cultures can be inferred. Heparin is known to play a role in the regulation of Ang II production.

Pathway 0 indicates that carboxypeptidase A3 (CPA3) is involved in the degradation of Ang II. This suggests that heparin deficiency may lead to a decrease in the degradation of Ang II, potentially resulting in increased levels of Ang II.

1080 Pathway 1 shows that angiotensin I converting enzyme (ACE) is responsible for the forma-1081 tion of Ang II. However, this pathway does not directly provide information about the effect 1082 of heparin deficiency on Ang II formation. Considering the information from pathways 0 and 1, it can be inferred that heparin deficiency 1084 may primarily affect the degradation of Ang II rather than its formation. Without heparin, the degradation of Ang II by carboxypeptidase A3 may be impaired, leading to increased levels of Ang II in the peritoneal cell cultures.", 1087 1088 "Reference Reasoning Process": "To determine the effect of heparin deficiency on the for-1089 mation and degradation of Ang II in peritoneal cell cultures, we can analyze the provided 1090 pathways for the role of mast cell proteases in Ang II production. 1091 The pathways provided do not directly mention heparin or its deficiency. However, we can infer the potential effects of heparin deficiency by understanding the role of mast cell proteases in Ang II production. 1093 Pathway 1 shows the conversion of Angiotensin I to Angiotensin III. Pathway 2 demonstrates 1094 the binding of Angiotensin I to angiotensin I converting enzyme (ACE), which is involved 1095 in the conversion of Angiotensin I to Angiotensin II. Pathway 3 shows the activation of angiotensin II receptor type 2 by Angiotensin II. Pathway 4 demonstrates the activation of AGTR1 and AGTR2 receptors by Angiotensin II. Pathway 5 shows the activation of angiotensin II receptor type 2 by Angiotensin A. 1099 Considering the information provided by these pathways, we can infer that heparin defi-1100 ciency may affect the activity of mast cell proteases, such as mouse mast cell protease 4 1101 (mMCP-4), which are involved in the conversion of Angiotensin I to Angiotensin II. Hep-1102 arin is a cofactor for the activation of mast cell proteases, and its deficiency may lead to reduced activity of these proteases. 1103 Therefore, the effect of heparin deficiency on the formation and degradation of Ang II in 1104 peritoneal cell cultures may be a reduction in the conversion of Angiotensin I to Angiotensin 1105 II, leading to decreased levels of Angiotensin II.", 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 Figure 10: Omission in Reasoning refers to errors where critical steps in the biological pathway involved in the question are omitted, leading to an incorrect final answer. In this case, the model's 1121 reasoning process considered the pathway involving the degradation of Ang II but missed the more 1122 important pathway of the conversion of Angiotensin I to Angiotensin II. This resulted in reasoning 1123 that led to an incorrect conclusion. 1124 1125 1126 1127 1128 1129 1130 1131 1132 **Category 4: Faulty in Reasoning** 1133 Faulty in Reasoning of CoT

ſ	"Question": "Enteropathogenic Escherichia coli (EPEC) is a major causative agent of in-
	fant diarrhoea in developing countries, and the EspF effector protein is injected from EPEC
	into host cells via a type III secretion system, disrupting host intestinal barrier function
	and initiating the mitochondrial death pathway. To clarify the manner in which EspF af-
	fects host cells, eukaryotic EspF-binding proteins were identified using affinity purification,
	and Abcf2, a protein of unknown function and member of the ABC-transporter family, was
	found to bind EspF. What is the effect of knocking down Abcf2 expression on EspF-induced
	caspase cleavage?",
	"Answer": "Knocking down Abcf2 expression increases EspF-induced caspase 9 and cas-
	pase 3 cleavage.",
	"Wrong Answer by Model": "The effect of knocking down Abcf2 expression on EspF-
	induced caspase cleavage is likely to decrease or inhibit caspase cleavage. Abcf2, as a
	binding protein of EspF, may play a role in the signaling pathway that leads to caspase
	activation and subsequent cleavage. By knocking down Abcf2 expression, the interaction
	between EspF and Abcf2 is disrupted, potentially preventing or reducing the activation of
	caspases and subsequent cleavage. This suggests that Abcf2 is involved in the EspF-induced
	mitochondrial death pathway and its knockdown may have a protective effect against the
	disruption of host intestinal barrier function caused by EPEC infection.",
	"Reference Reasoning Process": "To determine the effect of knocking down Abcf2 expres-
	sion on EspF-induced caspase cleavage, we should analyze the provided pathways for the
	interactions between EspF, Abcf2, and caspase.
	Pathway 0 provides information that EspF binds Abcf2, and this interaction inhibits Abcf2.
	Additionally, pathway 2 reveals that Abcf2 inhibits caspase 9, which is involved in the in-
	trinsic apoptotic pathway.
	When EspF binds Abcf2, it inhibits Abcf2's function. Since Abcf2 normally inhibits caspase
	9, the inhibition of Abcf2 by EspF would lead to an increase in caspase 9 activity. If Abcf2 expression is knocked down, its inhibitory effect on caspase 9 would be reduced.
	As a result, caspase 9 activity would increase, similar to the effect of EspF binding Abcf2.
	Therefore, knocking down Abcf2 expression would enhance EspF-induced caspase cleav-
	age. The reduction in Abcf2's inhibitory effect on caspase 9 would amplify the pro-apoptotic
	signal, leading to increased caspase cleavage.
	In summary, the effect of knocking down Abcf2 expression on EspF-induced caspase cleav-
	age would be an increase in caspase cleavage due to the reduced inhibitory effect of Abcf2
	on caspase 9.",

1170

Figure 11: Faulty Reasoning occurs when the reasoning path is correct, but there are significant 1171 errors in deducing the events within that pathway. In this case, the model's reasoning step proposes 1172 that EspF binds to Abcf2 and activates it, which is incorrect, as it actually inhibits Abcf2. As a 1173 result, the reasoning leads to an incorrect conclusion.

1174 1175

1177


1176 Faulty in Reasoning of PathSeeker


1178 "Question": "Bacterial pathogens often manipulate host immune pathways to establish acute 1179 and chronic infection, and many Gram-negative bacteria do this by secreting effector pro-1180 teins through a type III secretion system that alter the host response to the pathogen. In the 1181 case of Salmonella, the phage-encoded GogB effector protein targets the host SCF E3 type 1182 ubiquitin ligase through an interaction with Skp1 and the human F-box only 22 (FBXO22) 1183 protein. What is the effect of GogB-deficient Salmonella on tissue damage and colonization 1184 in the gut during long-term chronic infections?", "Answer": "GogB-deficient Salmonella cause extensive tissue damage and enhanced colo-1185 nization in the gut during long-term chronic infections.", 1186 1187 _____

1188 "Wrong Answer by Model": "Based on the provided pathways, the effect of GogB-deficient 1189 Salmonella on tissue damage and colonization in the gut during long-term chronic infections 1190 can be inferred. 1191 Pathway 0 indicates that the GogB effector protein targets the host SCF E3 type ubiquitin 1192 ligase through an interaction with Skp1 and the human F-box only 22 (FBXO22) protein. 1193 This pathway is associated with Salmonella infection. 1194 Pathways 1 and 2 provide information about other type III secretion system effectors (SseK1 1195 and SseK3) and their interactions with TNF-NFKB signaling pathways. These pathways are 1196 also linked to Salmonella infection. 1197 Pathway 3 shows the involvement of tumor necrosis factor (TNF) and its receptor TN-1198 FRSF1A in various signaling pathways, including Salmonella infection. 1199 Pathway 4 indicates the activation of NFKB, a transcription factor involved in inflammation and immune responses, by TNF. This pathway is associated with Salmonella infection. Pathways 5 and 6 provide information about the activation and inhibition of NFKB in-1201 hibitor alpha (NFKBIA) and its interaction with NFKB. These pathways are also linked 1202 to Salmonella infection. 1203 Pathway 7 shows the activation of MAPK8 (JNK) and its phosphorylation by FOS, which is associated with Salmonella infection. 1205 Based on the provided pathways, it can be inferred that GogB-deficient Salmonella would 1206 have a reduced ability to manipulate host immune pathways and alter the host response 1207 to the pathogen. This could result in decreased tissue damage and colonization in the gut 1208 during long-term chronic infections. However, the specific effects on tissue damage and 1209 colonization would require further investigation.", 1210 "Reference Reasoning Process": "Based on the pathways provided, the effect of GogB-1211 deficient Salmonella on tissue damage and colonization in the gut during long-term chronic 1212 infections can be inferred. 1213 GogB is a phage-encoded effector protein that targets the host SCF E3 type ubiquitin ligase 1214 through an interaction with Skp1 and the human F-box only 22 (FBXO22) protein (Pathway 1215 0). This interaction inhibits the NF-kappaB signaling pathway, which is a crucial pathway 1216 involved in inflammation and immune response. 1217 In the absence of GogB, the inhibition of the NF-kappaB signaling pathway is lifted, leading 1218 to an increase in the production of pro-inflammatory cytokines, such as TNF-alpha (Pathway 1219 3). This increase in inflammation can lead to tissue damage and exacerbate the symptoms of 1220 the infection. Furthermore, the NF-kappaB signaling pathway is also involved in the regulation of apoptosis (programmed cell death). The inhibition of this pathway by GogB can lead to a decrease 1222 in apoptosis, allowing the infected cells to survive and potentially leading to persistent in-1223 fection (Pathway 6). 1224 Additionally, GogB-deficient Salmonella may also have altered interactions with other host 1225 proteins, such as SifA, PipB2, and SopD2, which are involved in regulating microtubule 1226 dynamics and transport (Pathways 7, 9, and 10). These altered interactions can affect the 1227 ability of Salmonella to colonize and persist in the gut. 1228 Overall, the loss of GogB in Salmonella is likely to lead to increased tissue damage and 1229 inflammation during long-term chronic infections, as well as altered interactions with host 1230 proteins that can affect the ability of the bacteria to colonize and persist in the gut. 1231 In conclusion, the effect of GogB-deficient Salmonella on tissue damage and colonization in 1232 the gut during long-term chronic infections is likely to be an increase in tissue damage and inflammation, as well as altered interactions with host proteins that can affect the ability of 1233 the bacteria to colonize and persist in the gut.",

1236

Figure 12: Faulty Reasoning occurs when the reasoning path is correct, but there are significant errors in deducing the events within that pathway. In this case, the model reasoned along the NFkappaB signaling pathway but failed to deduce that a GogB deficiency leads to an increase in inflammation. Consequently, the final conclusion is incorrect.





The inner optimization problem, a Prize-Collecting Steiner Tree (PCST) problem, seeks to identify a connected subgraph that maximizes the total score of its nodes and edges while minimizing the edge costs, as utilized in (He et al., 2024). The outer optimization problem minimizes the difference between the optimal subgraph size and the target size. In practice, we apply a fast-solving method for the inner problem proposed by (Hegde et al., 2015) and employ a binary root search algorithm for the outer problem.

1356

1357 A.7 PATHSEEKER CASE 1358

1359 Please explore pathways to find relevant information regarding 1360 the following question: Worldwide, one of the most prevalent forms of chronic disease is alcoholic fatty liver, which may 1361 progress to more severe forms of liver injury. Chronic ethanol 1362 exposure is thought to cause enhanced hepatic lipogenesis and 1363 impaired fatty acid oxidation. Adiponectin is an adipose-derived 1364 hormone that has been associated with the development of 1365 alcoholic liver steatosis in rodent models. Does adiponectin have 1366 a protective role against alcoholic liver steatosis? 1367 1368 Action: Thought: To find information regarding the role of 1369 adiponectin in protecting against alcoholic liver steatosis, I 1370 can use the search_biopathway_subgraph_global tool to explore 1371 relevant biological pathways. I should convert all the question 1372 content into keywords to enhance retrieval quality. Action: 1373 search_biopathway_subgraph_global(['Adiponectin, 1374 adipose-derived hormone, associated with the development of 1375 alcoholic liver steatosis in rodent models, protective role against alcoholic liver steatosis, chronic ethanol exposure, 1376 enhanced hepatic lipogenesis, impaired fatty acid oxidation, 1377 liver injury']) 1378 End Action 1379 1380 State: 0) C00469: Ethanol; Ethyl alcohol; Methylcarbinol | 1381 406999: microRNA 217 MIR217 MIRN217 mir-217 | PCrel indirect 1382 effect activation | hsa04936: Alcoholic liver disease 1383 1) 406999: microRNA 217 MIR217 MIRN217 mir-217 | 23411: sirtuin 1 1384 SIRT1 SIR2 SIR2L1 SIR2alpha | PPrel inhibition indirect effect | 1385 hsa04936: Alcoholic liver disease 1386 2) 406999: microRNA 217 MIR217 MIRN217 mir-217 | 29896 6434: 1387 TRA2A AWMS1 HSU53209 | PPrel inhibition indirect effect | 1388 hsa04936: Alcoholic liver disease 1389 3) 29896 6434: TRA2A AWMS1 HSU53209 | 23175 64900 9663: LPIN1 PAP1 | PPrel activation | hsa04936: Alcoholic liver disease 1390 4) 23175 64900 9663: LPIN1 PAP1 | 6720: sterol regulatory element 1391 binding transcription factor 1 SREBF1 HMD IFAP2 SREBP1 bHLHd1 | 1392 PPrel inhibition | hsa04936: Alcoholic liver disease 1393 5) 6720: sterol regulatory element binding transcription factor 1 1394 SREBF1 HMD IFAP2 SREBP1 bHLHd1 | 6319 79966: SCD FADS5 MSTP008 1395 SCD1 SCDOS hSCD1 | GErel expression | hsa04152: AMPK signaling 1396 pathway hsa04936: Alcoholic liver disease 1397 6) 6720: sterol regulatory element binding transcription factor 1 1398 SREBF1 HMD IFAP2 SREBP1 bHLHd1 | 23175 64900 9663: LPIN1 PAP1 | 1399 GErel expression | hsa04936: Alcoholic liver disease 1400 7) C00469: Ethanol; Ethyl alcohol; Methylcarbinol | 51094 79602: 1401 ADIPOR1 ACDCR1 CGI-45 CGI45 PAQR1 TESBP1A | PCrel inhibition indirect effect | hsa04936: Alcoholic liver disease 1402 8) C00469: Ethanol; Ethyl alcohol; Methylcarbinol | 51422 53632 1403 5562 5563 5564 5565 5571: PRKAG2 AAKG AAKG2 CMH6 H91620p WPWS |

1404 PCrel inhibition indirect effect | hsa04936: Alcoholic liver 1405 disease 1406 9) C00469: Ethanol; Ethyl alcohol; Methylcarbinol | 50507: NADPH 1407 oxidase 4 NOX4 KOX KOX-1 RENOX | PCrel activation | hsa04936: 1408 Alcoholic liver disease 10) 50507: NADPH oxidase 4 NOX4 KOX KOX-1 RENOX | C22381: 1409 Reactive oxygen species; ROS | PCrel activation | hsa04936: 1410 Alcoholic liver disease 1411 11) C22381: Reactive oxygen species; ROS | 51422 53632 5562 5563 1412 5564 5565 5571: PRKAG2 AAKG AAKG2 CMH6 H91620p WPWS | PCrel 1413 inhibition indirect effect | hsa04936: Alcoholic liver disease 1414 12) C22381: Reactive oxygen species; ROS | 10000 207 208: AKT3 1415 MPPH MPPH2 PKB-GAMMA PKBG PRKBG RAC-PK-gamma RAC-gamma STK-2 | 1416 PCrel inhibition | hsa04936: Alcoholic liver disease 1417 13) 10000 207 208: AKT3 MPPH MPPH2 PKB-GAMMA PKBG PRKBG 1418 RAC-PK-gamma RAC-gamma STK-2 | 1499: catenin beta 1 CTNNB1 CTNNB 1419 EVR7 MRD19 NEDSDV armadillo | PPrel activation phosphorylation | 1420 hsa04936: Alcoholic liver disease 14) C22381: Reactive oxygen species; ROS | 5606 5608: MAP2K3 1421 MAPKK3 MEK3 MKK3 PRKMK3 SAPKK-2 SAPKK2 | PCrel activation | 1422 hsa04936: Alcoholic liver disease 1423 15) C00469: Ethanol; Ethyl alcohol; Methylcarbinol | 712 713 714: 1424 C1QA C1QD1 | PCrel activation | hsa04936: Alcoholic liver disease 1425 16) C00469: Ethanol; Ethyl alcohol; Methylcarbinol | 3605: 1426 interleukin 17A IL17A CTLA-8 CTLA8 IL-17 IL-17A IL17 ILA17 | 1427 PCrel indirect effect activation | hsa04936: Alcoholic liver 1428 disease 1429 17) C00084: Acetaldehyde; Ethanal | 51422 53632 5562 5563 5564 1430 5565 5571: PRKAG2 AAKG AAKG2 CMH6 H91620p WPWS | PCrel inhibition indirect effect | hsa04936: Alcoholic liver disease 1431 18) 9370: adiponectin C1Q and collagen domain containing ADIPOQ 1432 ACDC ACRP30 ADIPQTL1 ADPN APM-1 APM1 GBP28 | 51094 79602: ADIPOR1 1433 ACDCR1 CGI-45 CGI45 PAQR1 TESBP1A | PPrel activate activation | 1434 hsa04152: AMPK signaling pathway hsa04211: Longevity regulating 1435 pathway hsa04936: Alcoholic liver disease hsa04920: Adipocytokine 1436 signaling pathway N01788: ADIPOQ-ADIPOR signaling pathway 1437 19) 7132: TNF receptor superfamily member 1A TNFRSF1A CD120a FPF 1438 TBP1 TNF-R TNF-R-I TNF-R55 TNFAR TNFR1 TNFR55 TNFR60 p55 p55-R 1439 p60 | 6720: sterol regulatory element binding transcription 1440 factor 1 SREBF1 HMD IFAP2 SREBP1 bHLHd1 | PPrel indirect effect 1441 activation | hsa04936: Alcoholic liver disease 1442 1443 Action: Thought: I have gathered a large number of pathways 1444 related to the question. To better understand the role of 1445 adiponectin in protecting against alcoholic liver steatosis, I 1446 will check the neighboring pathways of Pathway 18, which is 1447 directly related to adiponectin. I will use the function search_biopathway_triple_N_hop_subgraph with history_line_id set 1448 to 18. The keywords are the same as previously used. 1449 Action: 1450 search_biopathway_triple_N_hop_subgraph(18, ['Adiponectin, 1451 adipose-derived hormone, associated with the development of 1452 alcoholic liver steatosis in rodent models, protective role 1453 against alcoholic liver steatosis, chronic ethanol exposure, 1454 enhanced hepatic lipogenesis, impaired fatty acid oxidation, 1455 liver injury']) 1456 End Action 1457

```
1458
     State: 20) C00219: Arachidonate; Arachidonic acid;
1459
      (5282112142)-Icosatetraenoic acid; cis-581114-Eicosatetraenoic
1460
      acid; 5Z8Z11Z14Z-Eicosatetraenoic acid; | 2180 2181 2182 23205
1461
     23305 51703: ACSL1 ACS1 FACL1 FACL2 LACS LACS1 LACS2 | pathway
1462
     bind to | hsa04216: Ferroptosis N01590: Arachidonate/Adrenic acid
1463
     metabolism
     21) 2180 2181 2182 23205 23305 51703 81616: ACSL1 ACS1 FACL1
1464
     FACL2 LACS LACS1 LACS2 | C00162: Fatty acid | PCrel | hsa04920:
1465
     Adipocytokine signaling pathway
1466
     22) 1376: carnitine palmitoyltransferase 2 CPT2 CPT1 CPTASE IIAE4
1467
     | 51 8310: ACOX1 ACOX AOX MITCH PALMCOX SCOX | ECrel compound |
1468
     hsa00071: Fatty acid degradation
1469
     23) 1376: carnitine palmitoyltransferase 2 CPT2 CPT1 CPTASE IIAE4
1470
      | 126129 1374 1375: CPTIC CATL1 CPTI-B CPTIP CPTI-B CPTIC SPG73 |
1471
     ECrel compound | hsa00071: Fatty acid degradation
1472
     24) 126129 1374 1375: CPTIC CATL1 CPTI-B CPTIP CPTI-B CPTIC SPG73
1473
     | 2180 2181 2182 23205 23305 51703 81616: ACSL1 ACS1 FACL1 FACL2
1474
     LACS LACS1 LACS2 | ECrel compound | hsa00071: Fatty acid
     degradation hsa04920: Adipocytokine signaling pathway
1475
     25) 4217: mitogen-activated protein kinase kinase 5 MAP3K5
1476
     ASK1 MAPKKK5 MEKK5 | 5609 6416: MAP2K7 JNKK2 MAPKK7 MEK MEK_7
1477
     MKK7 PRKMK7 SAPKK-4 SAPKK4 | PPrel activate activation
1478
     phosphorylation | hsa05418: Fluid shear stress and
1479
     atherosclerosis hsa04668: TNF signaling pathway hsa04936:
1480
     Alcoholic liver disease hsa05208: Chemical carcinogenesis -
1481
     reactive oxygen species N01407: Metals to JNK signaling pathway
1482
     26) 5609 6416: MAP2K7 JNKK2 MAPKK7 MEK MEK_7 MKK7 PRKMK7 SAPKK-4
1483
     SAPKK4 | 5599 5601 5602: MAPK8 JNK JNK-46 JNK1 JNK1A2 JNK21B1/2
1484
     PRKM8 | PPrel activate activation phosphorylation | hsa05418:
     Fluid shear stress and atherosclerosis hsa05135: Yersinia
1485
     infection hsa05417: Lipid and atherosclerosis hsa05167: Kaposi
1486
     sarcoma-associated herpesvirus infection hsa04620: Toll-like
1487
     receptor signaling pathway hsa04668: TNF signaling pathway
1488
     27) 5599 5601 5602: MAPK8 JNK JNK-46 JNK1 JNK1A2 JNK21B1/2 PRKM8
1489
     SAPK1 SAPK1c | 3667 8471 8660: IRS1 HIRS-1 | PPrel inhibition
1490
     phosphorylation | hsa04910: Insulin signaling pathway hsa05010:
1491
     Alzheimer disease hsa04930: Type II diabetes mellitus hsa04920:
1492
     Adipocytokine signaling pathway
1493
     28) 5599 5601 5602: MAPK8 JNK JNK-46 JNK1 JNK1A2 JNK21B1/2 PRKM8
1494
     SAPK1 SAPK1c | C00162: Fatty acid | PCrel
                                                 | hsa04930: Type II
1495
     diabetes mellitus
1496
      29) 4790 5970: NFKB1 CVID12 EBP-1 KBF1 NF-kB NF-kB1 NF-kappa-B1
     NF-kappaB NF-kappabeta NFKB-p105 | 2919 2920 2921: CXCL1 FSP GR01
1497
     GROa MGSA MGSA-a NAP-3 SCYB1 | PPrel activation expression |
1498
     hsa04621: NOD-like receptor signaling pathway hsa05167: Kaposi
1499
     sarcoma-associated herpesvirus infection hsa05417: Lipid and
1500
     atherosclerosis hsa05120: Epithelial cell signaling in
1501
     Helicobacter pylori infection hsa04936: Alcoholic liver disease
1502
     30) 4790 5970: NFKB1 CVID12 EBP-1 KBF1 NF-kB NF-kB1 NF-kappa-B1
1503
     NF-kappaB NF-kappabeta NFKB-p105 NFKB-p50 | 4792: NFKB inhibitor
1504
     alpha NFKBIA EDAID2 IKBA MAD-3 NFKBI | PPrel missing interaction
1505
     dissociation | hsa05215: Prostate cancer hsa05167: Kaposi
1506
     sarcoma-associated herpesvirus infection hsa05161: Hepatitis B
     hsa05220: Chronic myeloid leukemia hsa05160: Hepatitis C
1507
     hsa04936: Alcoholic liver disease hsa04657: IL-17 signaling
1508
     pathway
1509
     31) 4790 5970: NFKB1 CVID12 EBP-1 KBF1 NF-kB NF-kB1 NF-kappa-B1
1510
     NF-kappaB NF-kappabeta NFKB-p105 NFKB-p50 NFkappaB | 9021:
1511
     suppressor of cytokine signaling 3 SOCS3 ATOD4 CIS3 Cish3 SOCS-3
```

1512 SSI-3 SSI3 | GErel expression | hsa04920: Adipocytokine signaling 1513 pathway 1514 32) 9021: suppressor of cytokine signaling 3 SOCS3 ATOD4 CIS3 1515 Cish3 SOCS-3 SSI-3 SSI3 | 3667 8471 8660: IRS1 HIRS-1 | PPrel 1516 inhibition | hsa04920: Adipocytokine signaling pathway 33) 51094 79602: ADIPOR1 ACDCR1 CGI-45 CGI45 PAQR1 TESBP1A | 1517 C00076: Calcium cation; Ca2+; Calcium(2+); Calcium ion | PCrel 1518 indirect effect activation | hsa04152: AMPK signaling pathway 1519 hsa04936: Alcoholic liver disease 1520 34) C00076: Calcium cation; Ca2+; Calcium(2+); Calcium ion | 1521 10645: calcium/calmodulin dependent protein kinase kinase 2 1522 CAMKK2 CAMKK CAMKKB | PCrel activation | hsa04152: AMPK signaling 1523 pathway hsa04211: Longevity regulating pathway hsa04936: 1524 Alcoholic liver disease hsa04920: Adipocytokine signaling pathway 1525 35) 10645: calcium/calmodulin dependent protein kinase kinase 2 1526 CAMKK2 CAMKK CAMKKB | 51422 53632 5562 5563 5564 5565 5571: 1527 PRKAG2 AAKG AAKG2 CMH6 H91620p WPWS | PPrel activation phosphorylation | hsa04152: AMPK signaling pathway hsa04921: 1528 Oxytocin signaling pathway hsa04211: Longevity regulating pathway 1529 hsa04936: Alcoholic liver disease hsa04920: Adipocytokine 1530 signaling pathway 1531 36) 51094 79602: ADIPOR1 ACDCR1 CGI-45 CGI45 PAQR1 TESBP1A | 1532 5465: peroxisome proliferator activated receptor alpha PPARA 1533 NR1C1 PPAR PPAR-alpha PPARalpha hPPAR | PPrel indirect effect 1534 activation | hsa04920: Adipocytokine signaling pathway 1535 37) 5465: peroxisome proliferator activated receptor alpha PPARA 1536 NR1C1 PPAR PPAR-alpha PPARalpha hPPAR | 126129 1374 1375: CPT1C 1537 CATL1 CPT1-B CPT1P CPTI-B CPTIC SPG73 | GErel expression | 1538 hsa04920: Adipocytokine signaling pathway 38) 5465: peroxisome proliferator activated receptor alpha PPARA 1539 NR1C1 PPAR PPAR-alpha PPARalpha hPPAR | C00638: Long-chain fatty 1540 acid; Higher fatty acid | PCrel | hsa04920: Adipocytokine 1541 signaling pathway 1542 1543 Action: Thought: I have gathered a large number of pathways 1544 related to the question. To better understand the role of 1545 adiponectin in protecting against alcoholic liver steatosis, I 1546 will check the neighboring pathways of Pathway 18, which is 1547 directly related to adiponectin. I will use the function 1548 search_biopathway_triple_N_hop_subgraph with history_line_id set 1549 to 18. The keywords are the same as previously used. 1550 Action: 1551 search_biopathway_triple_N_hop_subgraph(18, ['Adiponectin, adipose-derived hormone, associated with the development of 1552 alcoholic liver steatosis in rodent models, protective role 1553 against alcoholic liver steatosis, chronic ethanol exposure, 1554 enhanced hepatic lipogenesis, impaired fatty acid oxidation, 1555 liver injury']) 1556 End Action 1557 1558 State: No new pathways were found besides those previously seen. 1559 1560 Action: Thought: Since no new pathways were found, I will finish 1561 the exploration. 1562 Answer: 1563 Finished. 1564 1565 State: You finished the task.



Figure 15: Uncertainty measured by entropy.

A.8 BASELINE DETAILS

Chain-of-Thought (CoT) (Wei et al., 2022; Kojima et al., 2022) prompting encourages language
models to generate step-by-step reasoning to solve tasks. We adopt CoT as the unaugmented standard method for LLM reasoning.

 Chain-of-Knowledge (CoK) (Li et al., 2023a) enhances chain-of-thought reasoning through knowledge verification, enabling language models to handle knowledge-intensive tasks. CoK first generates reasoning using chain-of-thought processes, then employs knowledge triples to verify the accuracy of the reasoning. While the reasoning of CoK is primarily driven by the language model, graph-based information is used for fact verification.

Think-of-Graph (ToG) (Sun et al., 2023) is an interactive reasoning method designed to actively navigate knowledge graphs for question solving. It primarily uses large language models to prune knowledge graph edges, thereby enabling efficient knowledge acquisition from complex graphs. The reasoning process in ToG is guided by graph navigation.

G-Retriever (He et al., 2024) is a graph retriever-augmented generation method that retrieves relevant subgraphs from a database and generates answers based on the retrieved subgraphs. While the original model in their work uses a graph encoder to encode graph data as a separate modality, in this work, we directly implement the graph-to-text encoder for improved versatility and better comparability with other methods.

1599

1566

1567

1568

1569 1570

1571

1572

1600 A.9 UNCERTAINTY MEASURE

Uncertainty We investigate whether graph augmentation can reduce the uncertainty in model responses. We measure this uncertainty in the discriminant task by calculating five times the entropy of the final results, as shown in Figure 15. Notably, graph augmentation reduces prediction uncertainty for LLaMA3-8B but not for GPT-3.5. This discrepancy may arise because GPT-3.5 tends to have fewer hallucinations, whereas LLaMA3-8B may exhibit overconfidence in some generations where it is uncertain.

- 1608
- 1609

1610 A.10 EVALUATION OF THE EVALUATOR QUALITY

As the generation task involves LLMs as evaluators, we assess the quality of the evaluation method by comparing the result with the human manual annotation score. The accuracy of LLaMA3.1 405B with human annotation is 96%, while the inconsistency lines in the case that the answer is close to the ground truth but the expression is general and missing details.

1616

- 1617 A.11 PERFORMANCE ON BIOLOGICAL DOMAINS
- 1619 Figure 16 illustrates both GPT-3.5 and LLaMA3 8B performance on BioMaze's different biological domains.




Figure 16: The radar chart of both GPT-3.5 and LLaMA3 8B performance on BioMaze's different biological domain.

1651 A.12 INTRODUCTION OF PATHWAY 1652

1653 Understanding biological systems is inherently complex due to the numerous interacting molecules, processes, and environmental factors involved. These systems operate with intricate interactions that 1654 result in non-linear, multi-layered, and dynamic behaviors. To address this complexity, biological 1655 researchers use pathway graphs as structured blueprints to simplify these systems into organized 1656 structures that consist of basic interactions. The linear reactions, cyclical relationships, or the local 1657 network of pathways offer snapshots of how a system behaves under specific conditions and enable 1658 researchers to predict how changes in one molecule or interaction can affect the entire system. Path-1659 way graphs also provide a structured, static representation of dynamic processes, helping researchers 1660 understand the sequence of events even as the system changes over time.

1662 1663

A.13 DETAILED RELATED WORK

1664 **Biological Scientific Question Answering** Previous studies have explored the potential of language 1665 models in the biological scientific domain. MEDHOP (Welbl et al., 2018) and PubMedQA (Jin 1666 et al., 2019) investigated biological scientific question answering in the form of reading comprehension. BioASQ-QA (Krithara et al., 2023) proposed a realistic question-answering benchmark for the 1668 actual information needs of biomedical experts. Beyond textual QA, several works have also studied 1669 multimodal scientific ability (Lu et al., 2022). Additionally, other studies have explored biomedical domain tasks (Vilares & Gómez-Rodríguez, 2019; Jin et al., 2021; Pal et al., 2022). Most existing tasks in the biological sciences concentrate on knowledge probing, assessing how well models 1671 understand biological information. In contrast, our work, BioMaze, is the first to focus on mod-1672 els' reasoning abilities within the biological scientific domain, specifically targeting phenomena 1673 observed in experiments about biological pathways.

A few studies have examined language models' ability to understand biological pathways. Chatpathway (Li et al., 2023b) and Azam et al. (2024) specifically investigated language models' capacity for completing biological pathways. However, these studies mainly focus on probing biological pathway knowledge, i.e., determining whether language models possess the relevant pathway information. In contrast, this work introduces a novel task that employs pathway models for practical biological pathway phenomenon reasoning, bridging the gap between pathway network knowledge and its implications. We compare this work with previous biological datasets in Table 8.

Table 8: Comparison of previous biological scientific question answering tasks and BioMaze.

	Domain	Question Form	Task Types
MEDHOP Welbl et al. (2018)	Scientific	Choice	Multi-hop reading comprehensior
PubMedQA Jin et al. (2019)	Scientific	True/False	Reading comprehension
HEAD-QA Vilares & Gómez-Rodríguez (2019)	Healthcare	Choice	Knowledge probing and reasoning
MedQA Jin et al. (2021)	Medical	Choice	Reading comprehension
MedMCQA Pal et al. (2022)	Medical	Choice	Knowledge probing and reasoning
BioASQ-QA Krithara et al. (2023)	Scientific	True/False and Open-Ended	Knowledege probing
ChatPathway Li et al. (2023b)	Pathway and biochemical	Open-Ended	Knowledge probing
Azam et al. (2024)	Pathway and gene	Choice	Knowledge probing
BioMaze (Ours)	Pathway for the scientific	True/False and Open-Ended	Reasoning in biological pathway

Graph-augmented Language Model Several studies have explored augmenting large language models (LLMs) with graph data. In particular, some works enhance LLMs by encoding graph data as text (Ye et al., 2023; Wang et al., 2024; Fatemi et al., 2023), or tuning LLMs specifically for graph-based tasks (Liu et al., 2023a; Tang et al., 2024; He et al., 2024; Zhao et al., 2023; He & Hooi, 2024). By augmenting LLMs with graph data, they have been applied to knowledge-based QA (Sun et al., 2023; He et al., 2024; Li et al., 2023a; Jin et al., 2024; Cheng et al., 2024), and to graph-oriented tasks like graph property prediction (Wang et al., 2024; He et al., 2023). A few other studies leverage graph structures during LLM reasoning to tackle complex tasks (Jiang et al., 2023; Besta et al., 2024).

Unlike tasks in previous works, this study addresses whether reasoning in biological systems can be
enhanced by pathway graphs, which act as a *structured blueprint* for reasoning about the system's
states. It is not sufficient to simply identify the correct paths in the pathway graph to find the answer.
Instead, it is necessary to perform deductive reasoning about the events that occur when the system
is intervened upon under specific conditions and to predict the resulting states and mechanisms of
the intervened system.

For large graph databases, most works enable LLMs to access graph data through retrieval mechanisms (He et al., 2024; Li et al., 2023a), while a few studies have explored using LLMs as interactive agents (Yao et al., 2023; Shinn et al., 2023; Zhao et al., 2024) to navigate and explore vast graph databases (Sun et al., 2023; Jin et al., 2024). In this work, we introduce an agent-based interactive graph exploration approach using subgraph navigation-based browsing, which is more efficient and offers enhanced navigation capabilities for pathway database.

1681

1682

- 1722
- 1723
- 1724
- 1725
- 1726 1727